Immunomedics (IMMU) 10-K 25 Aug 14 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Jun. 30, 2014	Aug. 22, 2014	Dec. 31, 2013
Document And Entity Information [Abstract]	'	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	30-Jun-14	'	'
Document Fiscal Year Focus	'2014	'	'
Document Fiscal Period Focus	'FY	'	'
Trading Symbol	'IMMU	'	'
Entity Registrant Name	'IMMUNOMEDICS INC	'	'
Entity Central Index Key	'0000722830	'	'
Current Fiscal Year End Date	'--06-30	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Filer Category	'Accelerated Filer	'	'
Entity Common Stock, Shares Outstanding	'	93,114,986	'
Entity Public Float	'	'	$4.60

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Jun. 30, 2014	Jun. 30, 2013
ASSETS	'	'
Cash and cash equivalents	$6,961,494	$41,326,000
Marketable securities	34,871,120	0
Accounts receivable, net of allowance for doubtful accounts of $88,609 and $49,265 at June 30, 2014 and 2013, respectively	674,617	622,830
Inventory	778,989	1,030,480
Other receivables	303,102	627,757
Prepaid expenses	972,320	432,660
Other current assets	180,678	1,175,883
Total current assets	44,742,320	45,215,610
Property and equipment, net	1,895,475	2,086,911
Value of life insurance policies	176,110	594,832
Other long-term assets	30,000	30,000
Total Assets	46,843,905	47,927,353
LIABILITIES AND STOCKHOLDERS' EQUITY	'	'
Accounts payable and accrued expenses	6,244,105	3,950,866
Deferred revenues	240,158	2,780,309
Total current liabilities	6,484,263	6,731,175
Other liabilities	1,500,244	1,400,728
Commitments and Contingencies (Note 12)	'	'
Stockholders' equity:	'	'
Preferred stock, $.01 par value; authorized 10,000,000 shares; no shares issued and outstanding at June 30, 2014 and 2013	0	0
Common stock, $.01 par value; authorized 135,000,000 shares; issued 93,113,480 shares and outstanding 93,078,755 shares at June 30, 2014; and issued 82,841,123 shares and outstanding 82,806,398 shares at June 30, 2013	931,134	828,411
Capital contributed in excess of par	300,080,804	265,688,408
Treasury stock, at cost: 34,725 shares at June 30, 2014 and 2013	-458,370	-458,370
Accumulated deficit	-261,465,638	-226,039,812
Accumulated other comprehensive income	261,837	161,830
Total Immunomedics, Inc. stockholders' equity	39,349,767	40,180,467
Noncontrolling interest in subsidiary	-490,369	-385,017
Total stockholders' equity	38,859,398	39,795,450
Total Liabilities and Stockholders' Equity	$46,843,905	$47,927,353

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Jun. 30, 2014	Jun. 30, 2013
Statement Of Financial Position [Abstract]	'	'
Accounts receivable, allowance for doubtful accounts	$88,609	$49,265
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	135,000,000	135,000,000
Common stock, shares issued	93,113,480	82,841,123
Common stock, shares outstanding	93,078,755	82,806,398
Treasury stock, shares	34,725	34,725

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive (Loss) Income (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Revenues:	'	'	'
License fee and other revenues	$4,623,333	$126,667	$28,418,000
Product sales	3,140,604	2,991,129	3,517,739
Research and development	1,277,668	1,844,201	798,088
Total revenues	9,041,605	4,961,997	32,733,827
Costs and Expenses:	'	'	'
Costs of goods sold	338,572	392,722	427,035
Costs of license fee and other revenues	1,189,170	0	0
Research and development	33,680,158	28,381,184	24,255,567
Sales and marketing	1,132,921	826,375	846,025
General and administrative	8,281,025	6,154,214	5,762,576
Total costs and expenses	44,621,846	35,754,495	31,291,203
Operating (loss) income	-35,580,241	-30,792,498	1,442,624
Arbitration settlement, net	0	16,739,282	0
Insurance proceeds received	0	2,637,879	0
Interest and other income, net	55,916	10,557	18,762
Foreign currency transaction gain (loss), net	938	-37,434	13,234
(Loss) income before income tax expense	-35,523,387	-11,442,214	1,474,620
Income tax expense	-7,791	-44,070	-209,785
Net (loss) income	-35,531,178	-11,486,284	1,264,835
Less net loss attributable to noncontrolling interest	-105,352	-104,761	-113,574
Net (loss) income attributable to Immunomedics, Inc.	-35,425,826	-11,381,523	1,378,409
(Loss) earnings per common share attributable to Immunomedics, Inc:	'	'	'
Basic	($0.42)	($0.15)	$0.02
Diluted	($0.42)	($0.15)	$0.02
Weighted average shares used to calculate (loss) earnings per common share:	'	'	'
Basic	84,631,567	78,040,005	75,481,007
Diluted	84,631,567	78,040,005	76,174,377
Other comprehensive income (loss), net of tax:	'	'	'
Foreign currency translation adjustments	100,094	81,669	-314,508
Unrealized loss on securities available for sale	-87	0	0
Other comprehensive income (loss)	100,007	81,669	-314,508
Net comprehensive (loss) income	-35,431,171	-11,404,615	950,327
Net comprehensive loss attributable to noncontrolling interest	-105,352	-104,761	-113,574
Net comprehensive (loss) income attributable to Immunomedics, Inc.	($35,325,819)	($11,299,854)	$1,063,901

Consolidated_Statements_of_Cha

Consolidated Statements of Changes in Stockholders' Equity (USD $)	Total	Common Stock [Member]	Capital Contributed in Excess of Par [Member]	Treasury Stock [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income [Member]	Noncontrolling Interest [Member]
Beginning balance at Jun. 30, 2011	$29,503,659	$754,630	$245,023,414	($458,370)	($216,036,698)	$394,669	($173,986)
Beginning balance, Shares at Jun. 30, 2011	'	75,463,066	'	'	'	'	'
Issuance of common stock purchase warrant	1,582,000	'	1,582,000	'	'	'	'
Exercise of stock options, net	171,815	592	171,223	'	'	'	'
Exercise of stock options, Shares	'	59,126	'	'	'	'	'
Stock based compensation	1,961,561	748	1,960,813	'	'	'	'
Stock based compensation, Shares	'	74,874	'	'	'	'	'
Other comprehensive income (loss)	-314,508	'	'	'	'	-314,508	'
Net income (loss)	1,264,835	'	'	'	1,378,409	'	-113,574
Ending balance at Jun. 30, 2012	34,169,362	755,970	248,737,450	-458,370	-214,658,289	80,161	-287,560
Ending balance, Shares at Jun. 30, 2012	'	75,597,066	'	'	'	'	'
Issuance of common stock, net	14,785,408	70,000	14,715,408	'	'	'	'
Issuance of common stock, Shares	'	7,000,000	'	'	'	'	'
Exercise of stock options, net	266,056	886	265,170	'	'	'	'
Exercise of stock options, Shares	'	88,594	'	'	'	'	'
Stock based compensation	2,018,494	1,555	2,016,939	'	'	'	'
Stock based compensation, Shares	'	155,463	'	'	'	'	'
Other comprehensive income (loss)	81,669	'	'	'	'	81,669	'
Share purchases of majority-owned subsidiary	-39,255	'	-46,559	'	'	'	7,304
Net income (loss)	-11,486,284	'	'	'	-11,381,523	'	-104,761
Ending balance at Jun. 30, 2013	39,795,450	828,411	265,688,408	-458,370	-226,039,812	161,830	-385,017
Ending balance, Shares at Jun. 30, 2013	'	82,841,123	'	'	'	'	'
Issuance of common stock, net	29,809,448	95,465	29,713,983	'	'	'	'
Issuance of common stock, Shares	'	9,546,474	'	'	'	'	'
Exercise of stock options, net	1,799,353	5,357	1,793,996	'	'	'	'
Exercise of stock options, Shares	'	535,730	'	'	'	'	'
Stock based compensation	2,886,318	1,901	2,884,417	'	'	'	'
Stock based compensation, Shares	'	190,153	'	'	'	'	'
Other comprehensive income (loss)	100,007	'	'	'	'	100,007	'
Net income (loss)	-35,531,178	'	'	'	-35,425,826	'	-105,352
Ending balance at Jun. 30, 2014	$38,859,398	$931,134	$300,080,804	($458,370)	($261,465,638)	$261,837	($490,369)
Ending balance, Shares at Jun. 30, 2014	'	93,113,480	'	'	'	'	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Cash flows from operating activities:	'	'	'
Net (loss) income	($35,531,178)	($11,486,284)	$1,264,835
Adjustments to reconcile consolidated net (loss) income to net cash (used in) provided by operating activities:	'	'	'
Depreciation and amortization	569,442	1,036,035	1,496,783
Amortization of deferred revenue	-2,674,347	-176,667	-128,956
Increase (decrease) in allowance for doubtful accounts	39,344	-5,544	22,797
Non-cash expense related to stock compensation	3,218,050	2,265,460	2,059,939
Gain on insurance claim for equipment failure	'	-137,879	'
Changes in operating assets and liabilities:	'	'	'
Accounts receivable	-62,652	66,755	54,225
Inventories	204,386	-617,954	-126,272
Other assets	798,835	-684,004	491,270
Accounts payable and accrued expenses	2,293,239	966,663	-501,710
Deferred revenue	134,196	2,774,345	108,692
Other liabilities	99,516	99,516	166,720
Net cash (used in) provided by operating activities activities	-30,911,169	-5,899,558	4,908,323
Cash flows from investing activities:	'	'	'
Purchases of marketable securities	-46,302,781	'	'
Proceeds from sales/maturities of marketable securities	11,431,661	'	'
Purchases of property and equipment	-378,006	-595,446	-568,133
Proceeds from partial liquidation of life insurance policy	400,000	'	'
Proceeds from insurance claim for equipment failure	'	137,879	'
Net cash used in investing activities	-34,849,126	-457,567	-568,133
Cash flows from financing activities:	'	'	'
Issuance of common stock, net of fees	29,809,448	14,785,408	'
Exercise of stock options, net	1,799,353	266,056	171,815
Tax withholding payments for stock compensation	-331,732	-246,966	-98,378
Share purchases of majority-owned subsidiary	'	-39,255	'
Issuance of common stock purchase warrant	'	'	1,582,000
Net cash provided by financing activities	31,277,069	14,765,243	1,655,437
Effect of changes in exchange rates on cash and cash equivalents	118,720	79,786	-255,141
(Decrease) increase in cash and cash equivalents	-34,364,506	8,487,904	5,740,486
Cash and cash equivalents at beginning of year	41,326,000	32,838,096	27,097,610
Cash and cash equivalents at end of year	6,961,494	41,326,000	32,838,096
Supplemental information for the statement of cash flows:	'	'	'
Cash paid for income taxes	$136,973	$135,023	$23,144

Business_Overview

Business Overview	12 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Business Overview	'
	1	Business Overview
	Immunomedics, Inc., a Delaware corporation (“Immunomedics” or the “Company”) is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. The Company has continued to transition its focus away from the development and commercialization of diagnostic imaging products in order to accelerate the development of its therapeutic product candidates, although the Company manufactures and commercializes its one product, LeukoScan® in territories where regulatory approvals have previously been granted in Europe, Canada and in certain other markets outside the U.S. LeukoScan® is indicated for diagnostic imaging for determining the location and extent of infection/inflammation in bone in patients with suspected osteomyelitis, including patients with diabetic foot ulcers. The Company has two foreign subsidiaries, Immunomedics B.V. in the Netherlands and Immunomedics GmbH in Darmstadt, Germany, to assist the Company in managing sales efforts and coordinating clinical trials in Europe. In addition, included in the accompanying financial statements is the majority-owned U.S. subsidiary, IBC Pharmaceuticals, Inc. (“IBC”), which has been working since 1999 on the development of novel cancer radiotherapeutics using patented pretargeting technologies with proprietary, bispecific antibodies.
	Immunomedics is subject to significant risks and uncertainties, including, without limitation, our inability to further identify, develop and achieve commercial success for new products and technologies; the possibility of delays in the research and development necessary to select drug development candidates and delays in clinical trials; the risk that clinical trials may not result in marketable products; the risk that the Company may be unable to successfully finance and secure regulatory approval of and market its drug candidates; its dependence upon pharmaceutical and biotechnology collaborations; the levels and timing of payments under its collaborative agreements; uncertainties about the Company’s ability to obtain new corporate collaborations and acquire new technologies on satisfactory terms, if at all; the development of competing products; its ability to protect its proprietary technologies; patent-infringement claims; and risks of new, changing and competitive technologies and regulations in the United States and internationally.
	Since its inception in 1982, Immunomedics’ principal sources of funds have been the private and public sale of debt and equity securities and revenues from licensing agreements, which could provide up-front and milestone payments, as well as funding of development costs and other licensing possibilities. The Company’s ability to raise capital through public and private debt or equity financings may be negatively impacted by the economy. There can be no assurances that financing will be available when needed on terms acceptable to it, if at all. If the Company were unable to raise capital on acceptable terms, its ability to continue its business would be materially and adversely affected. Furthermore, the terms of any such debt or equity financing may include covenants which may limit the Company’s future ability to manage the business. At the present time, the Company is unable to determine whether any of these future activities will be successful and, if so, the terms and timing of any definitive agreements.
	As of June 30, 2014 the Company has $41.8 million of cash, cash equivalents and marketable securities. The Company believes it has sufficient funds to continue its operations and research and development programs for at least the next twelve months. The Company’s cash requirements in fiscal year 2015 are expected to increase to approximately $41.0 million. However, the Company has the ability to reduce its cash flow spending requirements for fiscal year 2015 if necessary, after considering certain planned discretionary spending. The Company’s estimated increased expenses for fiscal year 2015 relates primarily to expenses related to the clivatuzumab tetraxetan Phase III clinical trial for the treatment of patients with pancreatic cancer as well as for expenses for the ongoing ADC programs. The Company will require additional funding in order to complete this Phase III clinical trial.
	The Company plans to continue pursuing sources of financing including, licensing arrangements, potential payments from partners, UCB S.A. (“UCB”) and The Bayer Group ("Bayer”), debt/equity financing, grants or other financing sources.
	The Company expects research and development activities to continue to expand over time and it does not believe it will have adequate cash to continue to conduct development of product candidates in line with its pipeline included in its long term corporate strategy. As a result, the Company will continue to require additional financial resources in order to conduct its research and development programs, clinical trials of product candidates and regulatory filings.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	2	Summary of Significant Accounting Policies
	Principles of Consolidation and Presentation
	The consolidated financial statements include the accounts of Immunomedics and its majority-owned subsidiaries. Noncontrolling interests in consolidated subsidiaries in the consolidated balance sheets represent minority stockholders’ proportionate share of the equity (deficit) in such subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
	Use of Estimates
	The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reported period. Actual results could differ from those estimates. The Company’s significant estimates and assumptions relate to revenue recognition, allowance for doubtful accounts, valuation of inventory and property and equipment, useful lives of property and equipment, accrued liabilities, stock compensation expenses, income tax uncertainties and other contingencies.
	Foreign Currencies
	For subsidiaries outside of the United States that operate in a local currency environment, income and expense items are translated to United States dollars at the monthly average rates of exchange prevailing during the year, assets and liabilities are translated at year-end exchange rates and equity accounts are translated at historical exchange rates. Translation adjustments are accumulated in a separate component of stockholders’ equity in the Consolidated Balance Sheets and the Consolidated Statements of Changes in Stockholders’ Equity and are included in the determination of comprehensive (loss) income in the Consolidated Statements of Comprehensive (Loss) Income. Transaction gains and losses are included in the determination of net (loss) income in the Consolidated Statements of Comprehensive (Loss) Income. As of June 30, 2014 and 2013, the cumulative unrealized foreign currency translation gain included in accumulated other comprehensive income was approximately $0.3 million and $0.2 million, respectively.
	Marketable securities
	Marketable securities, all of which are available-for-sale, consist of corporate debt securities and municipal bonds. Marketable securities are carried at fair value, with unrealized gains and losses, net of related income taxes, reported as accumulated other comprehensive income, except for losses from impairments which are determined to be other-than-temporary. Realized gains and losses, and declines in value judged to be other-than-temporary on available-for-sale securities are included in the determination of net (loss) income and are included in interest and other income (net), at which time the average cost basis of these securities are adjusted to fair value. Fair values are based on quoted market prices at the reporting date. Interest and dividends on available-for-sale securities are included interest and other income (net).
	Accounts Receivable
	Credit is extended to customers based upon an evaluation of the customer’s financial condition. Accounts receivable are recorded at net realizable value. The Company utilizes a specific identification accounts receivable reserve methodology based on a review of outstanding balances and previous activities to determine the allowance for doubtful accounts. The Company charges off uncollectible receivables at the time the Company determines the receivable is no longer collectible. The Company does not require collateral or other security to support financial instruments subject to credit risk.
	Concentration of Credit Risk
	Cash, cash equivalents and marketable securities are financial instruments that potentially subject the Company to concentration of credit risk. Immunomedics periodically invests its cash in debt instruments of banks and financial institutions with strong credit ratings. Immunomedics has established guidelines relative to diversification and maturities that are designed to help ensure safety and liquidity. These guidelines are periodically reviewed to take advantage of trends in yields and interest rates.
	Estimated Fair Value of Financial Instruments
	The Company has categorized its financial assets, based on the priority of the inputs to the valuation technique, into a three-level fair value hierarchy as set forth below. The Company does not have any financial liabilities that are required to be measured at fair value on a recurring basis. If the inputs used to measure the financial instruments fall within different levels of the hierarchy, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.
	Financial assets recorded on the consolidated balance sheets as of June 30, 2014 and 2013 are categorized based on the inputs to the valuation techniques as follows (in thousands):
		•		Level 1 – Financial assets whose values are based on unadjusted quoted prices for identical assets or liabilities in an active market which the Company has the ability to access at the measurement date (examples include active exchange-traded equity securities and most U.S. Government and agency securities).
		•		Level 2 – Financial assets whose value are based on quoted market prices in markets where trading occurs infrequently or whose values are based on quoted prices of instruments with similar attributes in active markets.
		•		Level 3 – Financial assets whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. These inputs reflect management’s own assumptions about the assumptions a market participant would use in pricing the asset.
			Level 1			Level 2		Level 3		Total
	June 30, 2014
	Money Market Funds		$	367		$	—	$	—	$	367
	Marketable Securities:
	U.S. Treasury Bonds			8,537			—		—		8,537
	U.S. Government Sponsored Agencies			7,457			—		—		7,457
	Corporate Debt Securities			18,877			—		—		18,877
	Total		$	35,238		$	—	$	—	$	35,238
	June 30, 2013
	Money Market Funds		$	38,327		$	—	$	—	$	38,327
	Total		$	38,327		$	—	$	—	$	38,327
	The money market funds noted above are included in cash and cash equivalents in the consolidated balance sheets. We recognize transfers between levels of the fair value hierarchy as of the date of the transaction. There were no transfers within the hierarchy during the fiscal years 2014 and 2013.
	Inventory
	Inventory, which consists of the finished product and work in process of LeukoScan, is stated at the lower of cost (on a first-in, first-out basis) or market, and includes materials, labor and manufacturing overhead.
	Property and Equipment and Impairment of Assets
	Property and equipment are stated at cost and are depreciated on a straight-line basis over the estimated useful lives (5-10 years) of the respective assets. Leasehold improvements are capitalized and amortized over the lesser of the remaining life of the lease or the estimated useful life of the asset. Immunomedics reviews long-lived assets for impairment whenever events or changes in business circumstances occur that indicate that the carrying amount of the assets may not be recoverable. Immunomedics assesses the recoverability of long-lived assets held and to be used based on undiscounted cash flows, and measures the impairment, if any, using discounted cash flows. To date the Company has not taken any impairment charges on property and equipment.
	Life Insurance Policies
	The Company has life insurance policies on Dr. David M. Goldenberg, the Company’s Chief Medical Officer and Chief Scientific Officer, which are for the benefit of the Company. When the Company is the beneficiary of the policy, and there are no other contractual arrangements between the Company and Dr. Goldenberg, the Company recognizes the amount that could be realized under the insurance arrangement as an asset in the Consolidated Balance Sheets.
	Revenue Recognition
	The Company has accounted for revenue arrangements that include multiple deliverables as a separate unit of accounting if both of the following criteria are met: a) the delivered item has value to the customer on a standalone basis, and b) if the right of return exists, delivery of the undelivered items is considered probable and substantially in the control of the vendor. If these criteria are not met, the revenue elements must be considered a single unit of accounting for purposes of revenue recognition. The Company allocates revenue consideration, excluding contingent consideration, based on the relative selling prices of the separate units of accounting contained within an arrangement containing multiple deliverables. Relative selling prices are determined using vendor specific objective evidence, if it exists; otherwise third-party evidence or the Company’s best estimate of selling price is used for each deliverable.
	Payments received under contracts to fund certain research activities are recognized as revenue in the period in which the research activities are performed. Payments received in advance that are related to future performance are deferred and recognized as revenue when the research projects are performed. Upfront nonrefundable fees associated with license and development agreements where the Company has continuing involvement in the agreement are recorded as deferred revenue and recognized over the estimated service period. The Company estimates the period of continuing involvement based on the best evidential matter available at each reporting period. If the estimated service period is subsequently modified, the period over which the upfront fee is recognized is modified accordingly on a prospective basis.
	In order to determine the revenue recognition for contingent milestones, the Company evaluates the contingent milestones using the criteria as provided by the Financial Accounting Standards Boards (“FASB”) guidance on the milestone method of revenue recognition, as explained in ASU 2010-17, “Milestone Method of Revenue Recognition”, at the inception of a collaboration agreement. The criteria requires that (i) the Company determines if the milestone is commensurate with either its performance to achieve the milestone or the enhancement of value resulting from the Company’s activities to achieve the milestone, (ii) the milestone be related to past performance, and (iii) the milestone be reasonable relative to all deliverable and payment terms of the collaboration arrangement. If these criteria are met then the contingent milestones can be considered as substantive milestones and will be recognized as revenue in the period that the milestone is achieved. Royalties are recognized as earned in accordance with the terms of various research and collaboration agreements.
	Revenue from the sale of diagnostic products is recorded when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed and determinable or collectability is reasonably assured. Allowances, if any, are established for uncollectible amounts, estimated product returns and discounts. Since allowances are recorded based on management’s estimates, actual amounts may be different in the future.
	Research and Development Costs
	Research and development costs are expensed as incurred. Costs incurred for clinical trials for patients and investigators are expensed as services are performed in accordance with the agreements in place with the institutions.
	Reimbursement of Research and Development Costs
	Reimbursement toward research and development costs under collaboration agreements are included as a reduction of research and development expenses. The Company records these reimbursements as a reduction of research and development expenses as the Company’s partner in the collaboration agreement has the financial risks and responsibility for conducting these research and development activities.
	Manufacturing Costs
	Manufacturing costs incurred in relation to the development of materials produced in order to fulfill contractual obligations are deferred and are recorded in other current assets until the product is delivered in accordance with the terms of the agreement.
	Income Taxes
	The Company uses the asset and liability method to account for income taxes, including the recognition of deferred tax assets and deferred tax liabilities for the anticipated future tax consequences attributable to differences between financial statements amounts and their respective tax bases. The Company reviews its deferred tax assets for recovery. A valuation allowance is established when the Company believes that it is more likely than not that its deferred tax assets will not be realized. Changes in valuation allowances from period to period are included in the Company’s tax provision in the period of change.
	The Company does not have an accrual for uncertain tax positions as of June 30, 2014 or 2013. The U.S. Federal statute of limitation remains open for the fiscal years 2009 onward. The Company’s tax returns filed in foreign jurisdictions remain open for the fiscal years 2010 onward. State income tax returns are generally subject to examination for a period of 3-5 years after filing of the respective return. The Company conducts business and files tax returns in New Jersey.
	Net (Loss) Income Per Share Allocable to Common Stockholders
	Basic net (loss) income per share is based upon the number of weighted average number of shares of common stock and vested restricted shares outstanding. Diluted net income per share is based upon the weighted average number of shares of common stock and dilutive potential shares of common stock outstanding. During fiscal years 2014 and 2013, no potential shares of common stock were included in the calculation since their affect would be anti-dilutive due to the operating losses. For fiscal year 2012, diluted net income per share is based upon the weighted average number of shares of common stock and dilutive potential shares of common stock outstanding. Potential shares of common stock that result from the assumed exercise of outstanding stock options and warrant shares, with exercise prices less than the average market price of the Company’s common stock are calculated under the treasury stock method. All other outstanding stock options and warrant shares have been excluded from the calculation.
	Comprehensive (Loss) Income
	Comprehensive (loss) income consists of consolidated net (loss) income, net unrealized loss on securities available for sale and foreign currency exchange translation adjustments and is presented in the Consolidated Statements of Comprehensive (Loss) Income.
	Stock-Based Compensation
	The Company’s 2006 Stock Incentive Plan (the “Plan”) permits the grant of options and shares to its employees and outside directors for up to eight million shares of common stock. A summary of this plan is provided in Note 7. The Company believes that such awards better align the interests of its employees with those of its shareholders. Option awards are generally granted with an exercise price equal to the market price of the Company’s stock at the date of grant; those option awards generally vest based on four years of continuous service and have seven year contractual terms. Certain options provide for accelerated vesting if there is a change in control (as defined in the Plan).
	The fair value of each option granted during the years ended June 30, 2014, 2013 and 2012 is estimated on the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions in the following table:
			Years ended June 30,
			2014		2013	2012
	Expected dividend yield		0%		0%	0%
	Expected option term (years)		3.85		5.35	5.32
	Expected stock price volatility		65%		69%	80%
Risk-free interest rate		0.03% - 1.79%		0.98% - 1.84%	1.01% - 2.46%
The weighted average fair value at the date of grant for options granted during the years ended June 30, 2014, 2013 and 2012 were $1.91, $2.12 and $2.23 per share, respectively. The Company uses historical data to estimate forfeitures. The expected term of options granted represents the period of time that options granted are expected to be outstanding. Expected stock price volatility was calculated based on the Company’s daily stock trading history. The weighted average of the expected option term declined to 3.85 years for year ended June 30, 2014, as a result of the issuance of short-term options to the former chief financial officer. Aside from these stock options the expected option term for other stock options granted during the year ended June 30, 2014 was 5.1 years. The risk-free rate for periods within the expected term of the option is based on the U.S. Treasury yield curve in effect at the time of grant. The lower risk-free interest rate results from the short-term rate for the stock options granted to the former chief financial officer.
As of June 30, 2014, the Company has 1,838,587 non-vested options and restricted stock shares outstanding. As of June 30, 2014, 2013 and 2012 there was $4.1 million, $3.6 million and $3.3 million, respectively, of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the Plan. That cost is being recognized over a weighted-average period of 2.52 years. The weighted average remaining contractual terms of the exercisable shares is 2.72 years and 2.59 years as of June 30, 2014 and 2013, respectively.
Financial Instruments
The carrying amounts of cash and cash equivalents, other current assets and current liabilities approximate fair value due to the short-term maturity of these instruments. The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents.
Insurance Proceeds
Insurance proceeds totaling $2.6 million were received during the fiscal year 2013 as a result of insurance claims from an equipment failure during the 2011 fiscal year. A cash payment for a business interruption insurance claim of $2.5 million was received, which had resulted from the equipment failure that had limited the production of materials necessary for certain research & product development. There was no such claim for fiscal year 2012. In addition, for fiscal year ended June 30, 2013 proceeds of $0.1 million was also recorded from a property claim regarding the same equipment failure. The proceeds received from these claims are classified as a separate other income component in the Consolidated Statement of Comprehensive (Loss) Income.
Recently Issued Accounting Pronouncements
In June 2014, the FASB issued Accounting Standard Update (“ASU”) 2014-012, “Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period”. This guidance clarifies that awards with these provisions should be treated as performance conditions that affect vesting, and do not impact the award’s estimated grant-date fair value. The amendments in this update are effective for annual reporting periods beginning after December 31, 2015, including interim periods, and early application is permitted. The Company is assessing ASU 2014-012’s impact and will adopt it when effective.
In June 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers”. This ASU was initiated as a joint project by the FASB and the International Accounting Standards Board (“IASB”) to clarify the principles for recognizing revenue and to develop a common revenue standard for U.S. GAAP and IFRS. For a public company, the amendments in this update are effective for annual reporting periods beginning after December 15, 2016, including interim periods, and early application is not permitted for public companies. The Company is assessing ASU 2014-09’s impact and will adopt it when effective.
In July 2013, the FASB issued ASU 2013-11, “Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carry-forward, a Similar Tax Loss, or a Tax Credit Carry-forward Exists”. This ASU will eliminate the diversity in practice in presentation of unrecognized tax benefits when a net operating loss carry-forward, a similar tax loss, or a tax credit carry-forward exists at the reporting date. This new guidance requires the netting of unrecognized tax benefits against a deferred tax asset for a loss or other carry-forward that would apply in settlement of the uncertain tax positions. Under the new guidance, unrecognized tax benefits will be netted against all available same-jurisdiction loss or other tax carry-forward that would be utilized, rather than only against carryforwards that are created by the unrecognized tax benefits. This guidance is effective prospectively, but allows optional retrospective adoption (for all periods presented), for reporting periods beginning after December 15, 2013. As this guidance relates to presentation only, the adoption of this guidance did not impact the Company’s financial statements.

Marketable_Securities

Marketable Securities	12 Months Ended
	Jun. 30, 2014
Investments Debt And Equity Securities [Abstract]	'
Marketable Securities	'
	3	Marketable Securities
	During the 2014 fiscal year, the Company invested $46.3 million of cash and cash equivalents into debt securities and municipal bonds, of which $11.4 million either matured or were sold during the fiscal year. Immunomedics adopted Accounting Standards Codification No. 320, Accounting for Investments – Debt and Equity Securities, to account for investments in marketable securities. Under this accounting standard, securities for which there are no positive intent and ability to hold to maturity, the securities are classified as available-for-sale and are carried at fair value. Unrealized holding gains and losses, which are deemed to be temporary, on securities classified as available-for-sale are carried as a separate component of accumulated other comprehensive income. Immunomedics considers all of its current investments to be available-for-sale. Marketable securities at June 30, 2014 consist of the following (in thousands):
			Amortized		Gross		Gross			Fair Value
			Cost		Unrealized		Unrealized
					Gain		(Loss)
	June 30, 2014
	U.S. Treasury Bonds		$	8,537	$	1	$	(1	)	$	8,537
	U.S. Government Sponsored Agencies			7,458		—		(1	)		7,457
	Corporate Debt Securities			18,876		12		(11	)		18,877
			$	34,871	$	13	$	(13	)	$	34,871
	Maturities of debt securities classified as available-for-sale were as follows at June 30, 2014 (in thousands):
			Fair Value		Net Carrying
					Amount
	Due within one year		$	25,336	$	25,449
	Due after one year through five years			9,535		9,603
			$	34,871	$	35,052

Inventory

Inventory	12 Months Ended
	Jun. 30, 2014
Inventory Disclosure [Abstract]	'
Inventory	'
	4	Inventory
	Inventory consisted of the following at June 30 (in thousands):
			2014		2013
	Work in process		$	—	$	914
	Finished goods			779		116
	Total		$	779	$	1,030

Property_and_Equipment

Property and Equipment	12 Months Ended
	Jun. 30, 2014
Property Plant And Equipment [Abstract]	'
Property and Equipment	'
	5	Property and Equipment
	Property and equipment consisted of the following at June 30 (in thousands):
			2014			2013
	Machinery and equipment		$	7,917		$	7,766
	Leasehold improvements			18,125			18,087
	Furniture and fixtures			933			933
	Computer equipment			2,233			2,044
				29,208			28,830
	Accumulated depreciation and amortization			(27,313	)		(26,743	)
			$	1,895		$	2,087
	Depreciation and amortization expense for the years ended June 30, 2014, 2013 and 2012 was $0.6 million, $1.0 million and $1.5 million, respectively.

Accounts_Payable_and_Accrued_E

Accounts Payable and Accrued Expenses	12 Months Ended
	Jun. 30, 2014
Payables And Accruals [Abstract]	'
Accounts Payable and Accrued Expenses	'
	6	Accounts Payable and Accrued Expenses
	Accounts payable and accrued expenses consisted of the following at June 30 (in thousands):
			2014		2013
	Trade accounts payable		$	2,366	$	980
	Clinical trial accruals			1,981		1,543
	Legal expenses			690		165
	Executive bonus			688		676
	Miscellaneous other current liabilities			519		587
			$	6,244	$	3,951

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Jun. 30, 2014
Equity [Abstract]	'
Stockholders' Equity	'
	7	Stockholders’ Equity
	Preferred Stock
	The Certificate of Incorporation of the Company authorizes 10,000,000 shares of preferred stock, $.01 par value per share. The preferred stock may be issued from time to time in one or more series, with such distinctive serial designations, rights and preferences as shall be determined by the Board of Directors. For each of the fiscal years ended June 30, 2014, 2013 and 2012 the Company has had no preferred stock outstanding.
	Common Stock
	In May 2014, the Company sold 9,546,474 shares of its common stock, composed of 9,000,000 shares of common stock initially offered and an additional 546,474 shares of common stock sold pursuant to the exercise of the underwriters’ over-allotment option. The public offering price of $3.35 per share of common stock resulted in net proceeds to the Company of approximately $29.8 million. The shares of common stock were sold pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission.
	In February 2013, the Company sold 7,000,000 shares of its common stock, composed of 6,086,956 shares of common stock initially offered and an additional 913,044 shares of common stock sold pursuant to the full exercise of the underwriters’ over-allotment option. The public offering price of $2.30 per share of common stock resulted in net proceeds to the Company of approximately $14.8 million. The shares of common stock were sold pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission.
	Stock Incentive Plans
	The Immunomedics, Inc. 2006 Stock Incentive Plan (“the Plan”) was created with the intention to promote the interests of the Company, by providing eligible persons with the opportunity to acquire a proprietary interest, or otherwise increase their proprietary interest, in the Company as an incentive to remain with the organization. At June 30, 2014 there were 9,927,700 shares of common stock authorized for issuance upon the exercise of stock options or the delivery under restricted stock units under the Plan.
	The Plan is divided into three separate equity incentive programs. These incentive programs consist of:
		•		Discretionary Grant Program under which eligible persons may be granted options to purchase shares of common stock or stock appreciation rights tied to the value of the common stock;
		•		Stock Issuance Program under which eligible persons may be issued shares of common stock pursuant to restricted stock awards, restricted stock shares, performance shares or other stock-based awards which vest upon completion of a designated service period or the attainment of pre-established performance milestones, or such shares of common stock may be a fully-vested bonus for services rendered; and
		•		Automatic Grant Program under which eligible non-employee Board members will automatically receive grants at designated intervals over their period of continued Board service.
	The Company believes that such awards better align the interests of its employees with those of its shareholders. Option awards are generally granted with an exercise price equal to the market price of the Company’s stock at the date of grant; those option awards generally vest based on four years of continuous service and have seven year contractual terms. Certain options provide for accelerated vesting if there is a change in control (as defined in the Plan). At June 30, 2014, 3,830,719 stock options were still available for future grant and shares of common stock were reserved for possible future issuance upon exercise of stock options both currently outstanding and which may be issued in the future.
	Each of the Company’s outside Directors who had been a Director prior to July 1st of each year is granted, at the annual shareholder meeting of each year, options to purchase shares of the Company’s common stock at fair market value on the grant date. The number of options to be issued is at the discretion of the Company’s Board of Directors. For fiscal years 2014, 2013 and 2012, stock options were granted to these outside directors to purchase an aggregate of 66,348 shares, 128,000 shares and 77,500 shares, respectively. The values of the granted options were $180 thousand, $225 thousand and $168 thousand for fiscal years ended 2014, 2013 and 2012, respectively. Stock options granted to outside directors are vested when granted. When an outside Director is elected to the Board of Directors, they are awarded options for 22,500 shares of the Company’s common stock. The Company recorded $246 thousand, $230 thousand and $168 thousand for stock-based compensation expense for these non-employee Board members stock options for the years ended June 30, 2014, 2013 and 2012, respectively.
	For the 2012 fiscal year as part of the Plan, each non-employee Board member who continued to serve in such capacity was automatically granted restricted stock units up to 5,000 shares of common stock. Beginning in the 2013 fiscal year, non-employee Board member who continues to serve shall receive on the date of the annual stockholders meeting an annual grant of non-qualified stock options and restricted stock units, equal in value to $45 thousand. For fiscal years 2014, 2013 and 2012, restricted stock units were granted to these outside directors in an aggregate of 38,216 units, 74,750 units and 25,000 units, respectively. The value of the units granted were $180 thousand, $225 thousand and $83 thousand for fiscal years 2014, 2013 and 2012, respectively. Restricted stock units granted to outside directors become vested within one year of grant date. The Company recorded $204 thousand, $154 thousand and $70 thousand for stock-based compensation expense for these non-employee Board members restricted stock units for the years ended June 30, 2014, 2013 and 2012, respectively.
	Information concerning options for the years ended June 30, 2014, 2013 and 2012 is summarized as follows:
			Number of Shares									Weighted Average Price
			2014			2013			2012			2014		2013		2012
	Options outstanding, beginning of year			5,726,874			5,799,100			6,471,975		$	3.3	$	3.72	$	4.92
	Options granted			1,216,729			759,900			349,000		$	4.79	$	3.59	$	3.4
	Options exercised			(535,730	)		(88,594	)		(59,126	)	$	3.36	$	3	$	2.91
	Options cancelled or forfeited			(1,099,256	)		(743,532	)		(962,749	)	$	4.35	$	6.96	$	11.7
	Options outstanding, end of year			5,308,617			5,726,874			5,799,100		$	3.41	$	3.3	$	3.72
	Options exercisable, end of year			4,121,942			4,572,716			4,686,364		$	3.18	$	3.21	$	3.81
	The aggregate intrinsic value of the outstanding and exercisable stock options as of June 30, 2014 and 2013 is $3.0 million and $12.3 million, respectively. The decline of the aggregate intrinsic value is primarily a result of the common stock price decline from $5.44 per share at June 30, 2013 to $3.65 per share at June 30, 2014. The aggregate intrinsic value is the sum of the amounts by which the quoted market price of the Company’s common stock exceeded the exercise price of the options at June 30, 2014, for those options for which the quoted market price was in excess of the exercise price. The total intrinsic value of options exercised during the 2014, 2013 and 2012 fiscal years was $0.8 million, $0.1 million and $33 thousand, respectively. Included in research and development and general and administrative expense categories the Company has recorded $1.5 million for stock-based compensation expense related to these stock options for each fiscal year ended June 30, 2014, 2013 and 2012.
	The following table summarizes information concerning options outstanding under the Plan at June 30, 2014:
	Range of		Number			Weighted			Weighted			Number		Weighted
	exercise price		outstanding			average			average			exercisable		average
			at June 30, 2014			exercise			remaining			at June 30, 2014		exercise
						price			term (yrs.)					price
	$1.59 - 3.00			2,078,288		$	2.43			1.56			2,074,663	$	2.43
	3.01 - 5.00			2,505,448			3.68			4.14			1,671,054		3.67
	5.01 - 7.00			724,881			5.28			6.39			376,225		5.21
				5,308,617		$	3.41			3.44			4,121,942	$	3.18
	At the Compensation Committee meeting held on August 16, 2013, the Company awarded an additional 136,452 restricted stock units to certain executive officers of the Company at the closing market price on that date ($5.13 per share). As of June 30, 2014 there was $1.2 million of total unrecognized compensation costs related to non-vested share-based compensation arrangements granted under the Plan for these executive officers, excluding performance stock units. That cost is being recognized over a weighted-average period of 2.31 years. The Company recorded $0.7 million, $0.6 million and $0.5 million for stock-based compensation expense for these executive officers for the fiscal years ended June 30, 2014, 2013 and 2012, respectively.
	On August 16, 2013, the Company also awarded certain executive officers Performance Units of up to 389,864 of restricted stock units which are subject to attainment of certain performance milestones as well as certain continued service requirements. All or a portion of the Performance Units shall vest based upon the level of achievement of the milestones set forth in each agreement, which is expected to be achieved within five years of the grant date. The Performance Units that vest based upon attainment of the Performance Milestone will be exercised based on a percentage basis on the attainment of anniversary dates. As of June 30, 2014, there are 389,864 Performance Units available if all performances are achieved within five years of grant date. The Company recorded $1.1 million for the stock-based compensation for the fiscal year ended June 30, 2014. There is $0.9 million of total unrecognized compensation cost related to these non-vested Performance Units granted as of June 30, 2014. That cost is being recognized over a weighted-average period of 2.0 years. The unrecognized compensation cost is subject to modification on a quarterly basis based on review of performance probability and requisite achievement periods.
	A summary of the Company’s non-vested restricted stock units at June 30, 2014, and changes during the year ended June 30, 2014 is presented below:
	Non-Vested Restricted Stock		Number of Awards
	Non-vested at July 1, 2013			488,575
	Restricted Unites Granted			192,168
	Performance Units Granted			389,864
	Vested/Exercised			(257,243	)
	Forfeited			(25,000	)
	Non-vested at June 30, 2014			788,364
	Accumulated Other Comprehensive Income
	The components of accumulated other comprehensive income were as follows:
			Currency			Net Unrealized Gains			Accumulated Other
			Translation			(Losses) on Available-			Comprehensive
			Adjustments			for-Sale Securities			Income
	Balance, July 1, 2011		$	394,669		$	—		$	394,669
	Change for the year			(314,508	)		—			(314,508	)
	Balance, June 30, 2012			80,161			—			80,161
	Change for the year			81,669			—			81,669
	Balance, June 30, 2013			161,830			—			161,830
	Other comprehensive income before reclassifications			100,094			7,430			107,524
	Amounts reclassified from accumulated other comprehensive income(a)			—			(7,517	)		(7,517	)
	Net current-period other comprehensive income			100,094			(87	)		100,007
	Balance, June 30, 2014		$	261,924		$	(87	)	$	261,837
	All components of accumulated other comprehensive income are net of tax, except currency translation adjustments, which exclude income taxes related to indefinite investments in foreign subsidiaries.
	(a)	For the fiscal year ended June 30, 2014, $7,517 was reclassified from accumulated other comprehensive income to interest and other income.

Earnings_Per_Share

Earnings Per Share	12 Months Ended
	Jun. 30, 2014
Earnings Per Share [Abstract]	'
Earnings Per Share	'
	8	Earnings Per Share
	Basic earnings per share are calculated using the weighted average number of outstanding shares of common stock including vested restricted shares. Diluted earnings per share computations, as calculated under the treasury stock method, include the weighted average number of shares of additional outstanding common stock issuable for stock options and restricted stock whether or not currently exercisable. Diluted earnings per share for the years presented do not include securities if their effect was anti-dilutive.
			2014			2013			2012
			(in thousands, except per share amounts)
	Net (loss) income attributable to Immunomedics, Inc.		$	(35,426	)	$	(11,382	)	$	1,378
	Basic earnings per share:
	Weighted average basic common shares outstanding			84,632			78,040			75,481
	Basic (loss) earnings per common share attributable to Immunomedics, Inc.		$	(0.42	)	$	(0.15	)	$	0.02
	Diluted earnings per share:
	Weighted average basic common shares outstanding			84,632			78,040			75,481
	Dilutive effect of restricted stock			—			—			82
	Dilutive effect of stock options outstanding			—			—			611
	Weighted average diluted common shares outstanding			84,632			78,040			76,174
	Diluted (loss) earnings per common share attributable to Immunomedics, Inc.		$	(0.42	)	$	(0.15	)	$	0.02
	Stock options and warrant shares excluded from the weighted average diluted common shares outstanding because their inclusion would have been anti-dilutive			6,309			6,727			5,699
	Restricted stock excluded from the weighted average diluted common shares outstanding because their inclusion would have been anti-dilutive			788			489			357

Income_Taxes

Income Taxes	12 Months Ended
	Jun. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	9	Income Taxes
	The expense (benefit) for income taxes is as follows (in thousands):
			Year Ended June 30,
			2014			2013			2012
	Federal
	Current		$	—		$	(38	)	$	126
	Deferred			—			—			—
	Total Federal			—			(38	)		126
	State
	Current			1			2			2
	Deferred			—			—			—
	Total State			1			2			2
	Foreign
	Current			7			80			82
	Deferred			—			—			—
	Total Foreign			7			80			82
	Total Expense		$	8		$	44		$	210
	A reconciliation of the statutory tax rates and the effective tax rates for each of the years ended June 30 is as follows:
			2014			2013			2012
	Statutory rate			(34.0	%)		(34.0	%)		34	%
	State income taxes (net of Federal tax benefit)			0	%		0	%		0.3	%
	Foreign income tax			0.1	%		0.1	%		(3.2	%)
	Change in valuation allowance			27.5	%		12.1	%		(716.2	%)
	NOL expiration			0	%		24.3	%		754.5	%
	R&D tax credit expiration			0	%		(3.4	%)		(72.8	%)
	Other			6.4	%		1.3	%		17.6	%
	Effective rate			0	%		0.4	%		14.2	%
	The tax effects of temporary differences that give rise to significant portions of the Company’s deferred tax assets as of June 30, 2014 and 2013 are presented below (in thousands):
			2014			2013
	Deferred tax assets:
	NOL carry forwards		$	66,699		$	53,941
	Research and development credits			12,264			11,707
	Property and equipment			4,055			4,369
	Other			5,479			8,705
	Total			88,497			78,722
	Valuation allowance			(88,497	)		(78,722	)
	Net deferred taxes		$	—		$	—
	A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized. The valuation allowances for fiscal years 2014 and 2013 have been applied to offset the deferred tax assets in recognition of the uncertainty that such tax benefits will be realized as the Company continues to incur losses. The differences between book income and tax income primarily relate to the temporary differences from depreciation and stock compensation expenses.
	At June 30, 2014, the Company has available net operating loss carry forwards for federal income tax reporting purposes of approximately $183.8 million and for state income tax reporting purposes of approximately $70.6 million, which expire at various dates between fiscal 2015 and 2034. Pursuant to Section 382 of the Internal Revenue Code of 1986, as amended, the annual utilization of a company’s net operating loss and research credit carry forwards may be limited if the Company experiences a change in ownership as defined in Section 382 of the Internal Revenue Code. As a result of certain financing arrangements, the Company may have experienced such ownership changes. Accordingly, the Company’s net operating loss carry forwards available to offset future federal taxable income arising before such ownership changes may be limited. Similarly, the Company may be restricted in using its research credit carry forwards arising before such ownership changes to offset future federal income tax expense. Of the deferred tax asset valuation allowance related to the net operating loss carry forwards, approximately $20.0 million relates to a tax deduction for non-qualified stock options.
	At June 30, 2014, the Company did not have any material unrecognized tax benefits and the Company does not anticipate that its unrecognized tax benefits will significantly change in the next twelve months. The Company will recognize potential interest and penalties related to income tax positions as a component of the provision for income taxes on the consolidated statements of comprehensive (loss) income in any future periods in which the Company must record a liability. The Company is subject to examination for U.S. Federal and Foreign tax purposes for 2010 and forward and for New Jersey 2011 and forward. The Company conducts business and files tax returns in New Jersey.

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Jun. 30, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions	'
	10	Related Party Transactions
	Certain of the Company’s affiliates, including members of its senior management and Board of Directors, as well as their respective family members and other affiliates, have relationships and agreements among themselves as well as with the Company and its affiliates, that create the potential for both real, as well as perceived, conflicts of interest. These include Dr. David M. Goldenberg, the Company’s Chairman, Chief Medical Officer and Chief Scientific Officer, Ms. Cynthia L. Sullivan, the President and Chief Executive Officer, who is the wife of Dr. David M. Goldenberg, and certain companies with which the Company does business, including the Center for Molecular Medicine and Immunology (“CMMI”) and IBC Pharmaceuticals, Inc.
	Dr. David M. Goldenberg
	Dr. David M. Goldenberg was the original founder of Immunomedics in 1982 and continues to play a critical role in its business. He currently serves as Chairman of the Board of Directors, Chief Medical Officer and Chief Scientific Officer, and is married to the Company’s President and Chief Executive Officer, Cynthia L. Sullivan. Dr. Goldenberg is a party to a number of agreements with the Company involving not only his services, but intellectual property owned by him. In addition, Dr. Goldenberg performs services for CMMI (see below for further details).
	License Agreement
	Pursuant to a License Agreement between Immunomedics and Dr. Goldenberg, certain patent applications owned by Dr. Goldenberg were licensed to Immunomedics at the time of Immunomedics’ formation in exchange for a royalty in the amount of 0.5% of the first $20.0 million of annual net sales of all products covered by any of such patents and 0.25% of annual net sales of such products in excess of $20.0 million. In November 1993, the ownership rights of Immunomedics were extended as part of, and superceded by, Dr. Goldenberg’s employment agreement, with Immunomedics agreeing to diligently pursue all ideas, discoveries, developments and products, into the entire medical field, which, at any time during his past or continuing employment by Immunomedics (but not when performing services for CMMI – see below), Dr. Goldenberg has made or conceived or hereafter makes or conceives, or the making or conception of which he has materially contributed to or hereafter contributes to, all as defined in the Employment Agreement.
	Employment Agreements
	On July 1, 2011, the Company entered into the Third Amended and Restated Employment Agreement with Dr. Goldenberg for his service to the Company as the Chief Scientific Officer and Chief Medical Officer (the “Goldenberg Agreement”), which terminates on July 1, 2016. The Goldenberg Agreement covers aspects of his compensation as well his duties and responsibilities at Immunomedics. Under the Goldenberg Agreement, Dr. Goldenberg’s annual base salary is at a minimum of $0.5 million, which shall be reviewed annually for appropriate increases by the Board of Directors or the Compensation Committee. Dr. Goldenberg is also eligible to participate in any Company incentive compensation plan in place for its senior level executives and is eligible to receive an annual discretionary bonus based upon certain performance standards to be determined by the Compensation Committee. Dr. Goldenberg’s annual bonus target is 50% of his annual base salary, subject to achievement of performance goals, with a potential payout from 0% to 150% of the target amount.
	Dr. Goldenberg is also eligible to receive certain additional incentive compensation during the agreement term. For any fiscal year in which the Company records an annual net loss, Dr. Goldenberg shall receive a sum equal to 0.75% of the consideration the Company receives from any licensing agreement, sale of intellectual property or similar transaction with any third party, with certain exceptions as defined in the Goldenberg Agreement. For any fiscal year in which the Company records net income, Dr. Goldenberg shall receive a sum equal to 1.50% of the Company’s Annual Net Revenue as defined in the Goldenberg Agreement for each such fiscal year, and thereafter throughout the non-competition period, as described in the Agreement.
	Dr. Goldenberg is also eligible to receive royalty payments on royalties received by the Company. For each fiscal year the Company shall pay Dr. Goldenberg a sum equal to a percentage of the annual royalties the Company receives on each of the products for which Dr. Goldenberg is an Inventor, and all products using, related to or derived from products for which Dr. Goldenberg is an Inventor. The percentage of royalties that the Company will pay to Dr. Goldenberg on each patented product will be determined based on the percentage of royalties that the Company must pay to external third parties.
	Dr. Goldenberg is also eligible to receive minimum payments of $150 thousand during each of the fiscal years, payable in equal quarterly payments, as an advance against the amounts due as additional incentive compensation, royalty payments and dispositions of undeveloped assets. In the event the Company completes a disposition of the Company’s undeveloped assets for which Dr. Goldenberg was an Inventor, the Company will pay Dr. Goldenberg a sum equal to at least twenty percent or more of the consideration the Company receives from each disposition. The Company’s obligation to compensate Dr. Goldenberg upon dispositions of undeveloped assets applies to all dispositions completed within the contract term or within three years thereafter.
	In accordance with the terms of the Goldenberg Agreement, additional compensation of $0.3 million was earned by Dr. Goldenberg for the fiscal year ended June 30, 2012 as a result of the Company’s profitability for that fiscal year. For the 2014 and 2013 fiscal years, Dr. Goldenberg received the minimum payment under the employment agreement.
	Finally, it is a condition to his employment agreement that Dr. Goldenberg be permitted to continue his involvement with CMMI, as discussed in greater detail below. Dr. Goldenberg also is compensated by IBC Pharmaceuticals as discussed in greater detail in these notes to the Consolidated Financial Statements.
	Cynthia L. Sullivan
	Effective July 1, 2011, the Company entered into the Fourth Amended and Restated Employment Agreement with Cynthia L. Sullivan pertaining to Ms. Sullivan’s service to the Company as the Company’s President and Chief Executive Officer (the “Amended Sullivan Agreement”), which terminated on June 30, 2014. Ms. Sullivan’s current annual base salary under the Amended Sullivan Agreement was $0.6 million, which was reviewed annually for appropriate increases by the Board or the Compensation Committee. Ms. Sullivan’s annual bonus target was 50% of her base salary, subject to achievement of performance goals, with a potential payout from 0% to 150% of the target amount. Ms. Sullivan was also be eligible to receive equity compensation awards under the Company’s 2006 Stock Incentive Plan, or any such successor equity compensation plan as may be in place from time to time. On June 19, 2014, the Company entered into the Fifth Amended and Restated Employment Agreement with Ms. Sullivan (the “Amended and Restated Sullivan Agreement”), which became effective July 1, 2014, (see Note 12 below).
	Relationships with The Center for Molecular Medicine and Immunology (CMMI)
	The Company’s product development has involved, to varying degrees, CMMI, for the performance of certain basic research and patient evaluations, the results of which are made available to the Company pursuant to a collaborative research and license agreement. The Company currently subleases approximately 1,000 square feet, at a rate of $30 thousand per year. Dr. Goldenberg is the founder, current President and a member of the Board of Trustees of CMMI. Dr. Goldenberg’s employment agreement permits him to devote such time as is necessary to fulfill his duties to the CMMI and IBC Pharmaceuticals, Inc., provided that such duties do not materially interfere with his ability to perform any of his obligations under the Goldenberg Agreement. Certain of the Company’s consultants have employment relationships with CMMI, and Dr. Hans Hansen, the Company’s emeritus executive officer, is an adjunct member of CMMI. CMMI’s management and fiscal operations are the responsibility of CMMI’s Board of Trustees.
	The Company has reimbursed CMMI for expenses incurred on behalf of the Company, including amounts incurred pursuant to research contracts, in the amount of approximately $32 thousand and $0.2 million during the years ended June 30, 2013 and 2012, respectively. There were no such payments for the year ended June 30, 2014. For fiscal 2012, the Company also reimbursed one-half of the clean-up cost for the disposal of materials related to the Company’s contract research at the CMMI former facility. In fiscal years ended June 30, 2014, 2013 and 2012, the Company incurred $26 thousand, $60 thousand and $68 thousand, respectively, of legal expenses for patent related matters for patents licensed to Immunomedics from CMMI. However, any inventions made independently of the Company at CMMI are the property of CMMI.
	IBC Pharmaceuticals
	IBC Pharmaceuticals, Inc. (“IBC”) is a majority owned subsidiary of Immunomedics, Inc.
	As of June 30, 2014, the shares of IBC Pharmaceuticals, Inc. were held as follows:
	Stockholder		Holdings	Percentage of Total
	Immunomedics, Inc.		5,615,124 shares of Series A Preferred Stock		73.46	%
	Third Party Investors		628,282 shares of Series B Preferred Stock		8.22	%
	David M. Goldenberg Millennium Trust		1,399,926 shares of Series C Preferred Stock		18.32	%
					100	%
	In the event of a liquidation, dissolution or winding up of IBC, the Series A, B and C Preferred Stockholders would be entitled to $0.6902, $5.17 and $0.325 per share (subject to adjustment), respectively. The Series A and B stockholders would be paid ratably until fully satisfied. The Series C stockholders would be paid only after the Series A and B stockholders have been fully repaid. These liquidation payments would be made only to the extent the assets of IBC are sufficient to make such payments.
	In each of the fiscal years 2014, 2013 and 2012, Dr. Goldenberg received $79 thousand, $78 thousand and $55 thousand, respectively in compensation for his services to IBC. At June 30, 2014, Dr. Goldenberg was a director of IBC, while Cynthia L. Sullivan, Peter P. Pfreundschuh, Vice President of Finance and CFO of Immunomedics, Inc., and Phyllis Parker, Director of Administration of Immunomedics, Inc., have served as the President, Treasurer and Secretary, respectively, of IBC.

License_and_Collaboration_Agre

License and Collaboration Agreements	12 Months Ended
	Jun. 30, 2014
Text Block [Abstract]	'
License and Collaboration Agreements	'
	11	License and Collaboration Agreements
	Algeta ASA
	In January 2013 the Company entered into a collaboration agreement with Algeta ASA for the development of epratuzumab to be conjugated with Algeta’s proprietary thorium-227 alpha-pharmaceutical payload. On August 2, 2013, an amendment to the collaboration agreement was entered into between the two companies modifying certain delivery and supply parameters. Under the terms of this agreement, as amended, the Company was required to manufacture and supply clinical-grade antibody to Algeta, which has rights to evaluate the potential of a Targeted Thorium Conjugate (TTC), linking thorium-227 to epratuzumab, for the treatment of cancer. Algeta will fund all preclinical and clinical development costs up to the end of Phase I testing. Upon successful completion of Phase I testing, the parties shall negotiate terms for a license agreement at Algeta’s request. The Company and Algeta have agreed to certain parameters to be included in the collaboration agreement. Under the terms of the collaboration agreement, as amended, Immunomedics received an upfront cash payment and other payments which have been recognized as revenue as the aspects of delivery for the clinical supply material have been satisfied. For the year ended June 30, 2014, the Company recognized $4.6 million of revenue under this arrangement, which has been included in license fee and other revenues, while the related costs of $1.2 million is included in cost of license fee and other revenue. As of June 30, 2014 the Company has recognized all of the initial cash payments. On March 6, 2014, The Bayer Group (“Bayer”) completed its voluntary takeover of 98.2% shares and voting rights in Algeta ASA which made Algeta ASA a majority-owned subsidiary of Bayer. Bayer has subsequently acquired the remaining shares of the minority shareholders and has had the program with Immunomedics formally transferred to Bayer (Algeta).
	Takeda Pharmaceutical/Nycomed GmbH
	On July 11, 2008, the Company entered into the Nycomed Agreement with Nycomed providing Nycomed a worldwide license to develop, manufacture and commercialize veltuzumab, the Company’s humanized anti-CD20 antibody, in the subcutaneous formulation, for the treatment of all non-cancer indications. The Company retained the rights to develop, manufacture and commercialize veltuzumab in the field of oncology. On September 30, 2011, Takeda Pharmaceutical Company Limited completed its acquisition of Nycomed and made Nycomed a wholly owned subsidiary of Takeda (“Takeda-Nycomed”).
	Takeda-Nycomed was solely responsible for the development, manufacturing, regulatory approval and commercialization of veltuzumab and the development, manufacturing and regulatory approval of the subcutaneous formulation for all non-cancer indications. The Company’s major obligations were to complete the research and development activities as specified in the Nycomed Agreement and to manufacture and supply veltuzumab to Takeda-Nycomed for the quantity of materials and for the period of time specified in the Nycomed Agreement. The Company has completed all of its obligations under the agreement, namely its manufacturing and supply obligations and its responsibilities in the Phase I/II study in immune thrombocytopenic purpura (“ITP”).
	On October 3, 2013, the Company received notification from Takeda Pharmaceutical Company Limited/Nycomed GmbH of termination of the Nycomed Agreement. The notification was received subsequent to the Company’s filing of arbitration proceedings in an effort to resolve the dispute the Company has with Nycomed and Takeda concerning delays in the development of veltuzumab, which the Company argues is a material breach of the licensing agreement.
	As a result of the termination, all rights to veltuzumab revert to the Company and all parties have had discussions regarding the transition of veltuzumab back to the Company and certain materials have been returned to the Company. In addition, the Company will continue to pursue the arbitration procedure to address its claim for damages due to, among other things, delays in the development of veltuzumab.
	On October 11, 2013, Takeda and Takeda-Nycomed filed their Statement of Defense and Counterclaims alleging, among other things, that the Company wrongfully terminated the licensing agreement and caused Takeda and Takeda-Nycomed to suffer significant damages and delays in developing veltuzumab. The Company responded by filing its own Statement of Defense on November 12, 2013, denying Takeda and Takeda-Nycomed’s allegations and contesting Takeda or Takeda-Nycomed’s rights to any relief. An arbitrator was appointed later that month. On December 20, 2013 the arbitrator issued a pre-hearing scheduling order and discovery in the arbitration is proceeding in accordance with that schedule. The hearing portion of the arbitration process was completed on August 21, 2014. Each party's counsel is expected to file post-hearing submissions in October 2014. The decision by the arbitrator is expected within two months of the post-hearing submissions.
	UCB, S.A.
	On May 9, 2006, the Company entered into an agreement with UCB, S.A., referred to herein as UCB, providing UCB an exclusive worldwide license to develop, manufacture, market and sell epratuzumab for the treatment of all non-cancer indications, referred to herein as the UCB Agreement. Under the terms of the UCB Agreement, the Company received from UCB a non-refundable cash payment totaling $38.0 million. On December 27, 2011, the Company entered into the Amendment Agreement with UCB, referred to herein as the Amendment Agreement. The Amendment Agreement provided UCB the right to sublicense epratuzumab, subject to obtaining the Company’s prior consent, to a third party for the United States and certain other territories. As of June 30, 2014, UCB has not executed a sublicense agreement with a third-party.
	The Company also issued to UCB on December 27, 2011 a 5-year warrant to purchase one million shares of the Company’s common stock, par value $0.01 per share, at an exercise price of $8.00 per share. In exchange for the right to sublicense its rights in epratuzumab to a third party and the warrant issuance, the Company received a non-refundable cash payment of $30.0 million in January 2012. Further, under the terms of the Amendment Agreement, UCB surrendered its buy-in right with respect to epratuzumab in the field of oncology, which had been granted under the UCB Agreement.
	Collectively, pursuant to the UCB Agreement and the Amendment Agreement, the Company is entitled to receive (i) up to $145.0 million in cash payments and $20.0 million in equity investments in regulatory milestone payments and (ii) up to $260.0 million related to the achievement of specified product sales milestones. The Company is also entitled to product royalties ranging from mid-teen to mid-twenty percentage of aggregate annual net sales under the UCB Agreement during the product royalty term. No development milestone, commercialization milestone or royalty payments were achieved through March 18, 2014. There can be no assurance that the development or commercialization milestones or royalty payment thresholds under the UCB Agreement and Amendment Agreement will be met and therefore there can be no assurance that the Company will receive such future payments.
	The Agreement commenced on May 9, 2006 and shall terminate in accordance with the terms thereof or by mutual written consent, unless UCB decides to cease all development and commercialization of epratuzumab pursuant to the Agreement. Either the Company or UCB has the right to terminate the Agreement by notice in writing to the other party upon or after any material breach of the Agreement by the other party, if the other party has not cured the breach within 60 days after written notice to cure has been given, with certain exceptions. Upon termination of the Agreement, among other things, all rights and licenses granted by the Company to UCB shall terminate, all rights of UCB under the Immunomedics Patent Rights (as defined in the Agreement) and Immunomedics Know-How (as defined in the Agreement) shall revert to the Company, and UCB shall cease all use of the Immunomedics Patent Rights and Immunomedics Know-How. Further, all regulatory filings and Approvals (as defined in the Agreement) and any other documents relating to or necessary to further develop and commercialize the Licensed Compound (as defined in the Agreement) and Licensed Products (as defined in the Agreement), including, without limitation, all sublicenses granted by UCB, and all of UCB’s right, title and interest therein and thereto, shall be assigned to the Company at the Company’s option. No additional amounts shall be payable on events occurring after the effective date of termination.
	In accordance with the applicable accounting guidance for multiple-element revenue arrangements (ASU 2009-13), the Company evaluated the terms and conditions of the Amendment Agreement to determine if such amendments represented a material modification of the UCB Agreement. A material modification requires an entity to account for an arrangement that was entered into prior to the prospective adoption of ASU 2009-13 under the provisions of ASU 2009-13 and to determine if an adjustment is required on the date of modification to reflect the accounting that would have resulted had the entity applied the requirements of ASU 2009-13 from the date of the inception of the contract. Given the additional rights provided to UCB under the Amendment Agreement, the warrant issuance, and the additional contingent revenue payments, the Company concluded that the Amendment Agreement did represent a material modification of the UCB Agreement.
	The Company assessed its obligations under the Amendment Agreement and concluded that it had two deliverables and two units of accounting including 1) providing UCB with the right to sublicense its rights in epratuzumab and 2) the warrant issuance, both of which were satisfied upon execution of the Amendment Agreement on December 27, 2011. UCB is fully responsible for all development and commercialization of epratuzumab. The Company has no other obligations for the development of the product under terms of the UCB Agreement and the Amendment Agreement. As such, the $30.0 million non-refundable fee that was earned upon execution of the Amendment Agreement was allocated to the two units of accounting using a relative selling price method for each deliverable. Accordingly, as all deliverables were satisfied on December 27, 2011, the Company recorded $28.4 million of license fee revenue, which was determined by the Company to represent an appropriate selling price for such rights granted to UCB, in the year-ended June 30, 2012 and recorded the fair value of the warrant within capital contributed in excess of par in the amount of $1.6 million. All contingent revenue payments relate specifically to the license and sublicense rights provided to UCB in the UCB Agreement and Amendment Agreement, respectively. However, such payments are not included in allocable consideration until the events that give rise to the contingent consideration occur, even if it is probable that such events will occur.
	The Company used the Black-Scholes option pricing model to determine the $1.6 million estimated fair value of the 5-year warrant as of December 27, 2011. The warrant was accounted for as an equity transaction, as the warrant represents a freestanding financial instrument entitling UCB to a fixed number of unregistered shares for a fixed price, is not publicly tradable or transferable, does not have a cash or net settlement option and can only be exercised by UCB. The significant assumptions used in preparing the Black-Scholes option pricing model include (i) Immunomedics common stock price volatility of 80%, (ii) the market yield risk free interest rate of 0.96% (estimated at the U.S. Treasury Five-Year Bond Rate on December 27, 2011), (iii) option price of the warrant at conversion ($8.00/share), (iv) the common stock price of $3.37/share at the close of business on December 27, 2011, (v) a dividend yield of 0%, and (vi) the effective maturity period of five years (life of the warrant).
	Given that the Company’s performance obligations have been satisfied upon execution of the Amendment Agreement and are not provided for over time, development milestone payments do not qualify for the milestone method of revenue recognition and are not deemed to be substantive. However, as the Company has no future performance obligations related to the UCB Agreement and Amendment Agreement, revenue will be recognized when earned upon achievement of the agreed upon milestones.
	In accordance with the Company’s accounting policy and applicable revenue recognition guidance, royalties are not evaluated under the milestone method and are recognized when earned. Similarly, the Company treats sales-based milestone payments as royalties. As such, commercialization milestone payments, which are related to the achievement of specified product sales thresholds, are not evaluated under the milestone method and are recognized into revenue when earned.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Jun. 30, 2014
Commitments And Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	12	Commitments and Contingencies
	Employment Contracts
	Effective July 1, 2014, the Company entered into the Fifth Amended and Restated Employment Agreement with Cynthia L. Sullivan pertaining to Ms. Sullivan’s service to the Company as the Company’s President and Chief Executive Officer (see Note 15). Ms. Sullivan’s annual base salary under this new agreement is $0.6 million, which shall be reviewed annually for appropriate increases by the Board of Directors or the Compensation Committee.
	Effective July 1, 2011 the Company entered into the Third Amended and Restated Employment Agreement with Dr. David M. Goldenberg pertaining to Dr. Goldenberg’s service to the Company as its Chief Scientific Officer and Chief Medical Officer (the “Goldenberg Agreement”). This agreement provides for a guaranteed salary of $0.5 million and $0.2 million for guaranteed royalties for Dr. Goldenberg for the fiscal years 2013 through 2016 (see Note 10).
	Operating Lease
	Immunomedics is obligated under an operating lease for facilities used for research and development, manufacturing and office space, expiring in October 2031 at a base annual rate of $0.8 million, which is fixed through October 2016 and increases thereafter every five years. The Company currently subleases approximately 1,000 square feet to CMMI for their operations. Rental expense related to this lease was approximately $0.8 million for fiscal years 2014, 2013 and 2012.
	The minimum lease commitments for the non-cancelable term of the facility lease described above are as follows for fiscal years (in thousands):
	2015		$	838
	2016		$	838
	2017		$	929
	2018		$	974
	2019		$	974
	Thereafter		$	12,710
	Legal Matters
	Former Licensing Partner:
	On October 3, 2013, the Company received notification from Takeda Pharmaceutical Company Limited/Nycomed GmbH of termination of the License and Collaboration Agreement that it entered into with Nycomed which provided Nycomed a worldwide license to develop, manufacture and commercialize veltuzumab, in the subcutaneous formulation, for the treatment of all non-cancer indications, referred to herein as the Nycomed Agreement. The notification was received subsequent to the Company’s filing of arbitration proceedings in an effort to resolve the dispute it has with Nycomed and Takeda concerning delays in the development of veltuzumab, which the Company argues is a material breach of the Nycomed Agreement. As a result of the termination, all rights to veltuzumab revert to the Company and all parties have had discussions regarding the transition of veltuzumab back to the Company and certain materials have been returned to the Company. In addition, the Company will continue to pursue the arbitration procedure to address its claim for damages due to, among other things, delays in the development of veltuzumab.
	On October 11, 2013, Takeda and Takeda-Nycomed filed their Statement of Defense and Counterclaims alleging, among other things, that the Company wrongfully terminated the Nycomed Agreement and caused Takeda and Takeda-Nycomed to suffer significant damages and delays in developing veltuzumab. The Company responded by filing its own Statement of Defense on November 12, 2013, denying Takeda and Takeda-Nycomed’s allegations and contesting Takeda or Takeda-Nycomed’s rights to any relief. An arbitrator was appointed later that month. On December 20, 2013 the arbitrator issued a pre-hearing scheduling order and discovery in the arbitration is proceeding in accordance with that schedule. The hearing portion of the arbitration process was completed on August 21, 2014. Each party's counsel is expected to file post-hearing submissions in October 2014. The decision by the arbitrator is expected within two months of the post-hearing submission, (see Note 11).
	The Company does not believe these matters, even if adversely adjudicated or settled, would have a material adverse effect on its consolidated financial condition, results of operations or cash flows.
	Shareholder complaints:
	Two separate shareholder derivative complaints have been filed against the Company. First, on March 24, 2014, a complaint styled Kops v. Goldenberg, et al., was filed in the Superior Court of New Jersey, Chancery Division, General Equity Part, Morris County. Second, on April 18, 2014, a complaint styled Breitman v. Sullivan, et al., was filed in the United States District Court for the District of New Jersey. The complaints allege, among other things, that the Company and certain directors and officers breached their fiduciary duties for disseminating false and misleading information relating to the termination of the Nycomed Agreement. In particular, the complaints allege that defendants failed to make timely disclosure concerning a dispute concerning a delay in the development of veltuzumab. On October 9, 2013, the Company announced that the Nycomed Agreement was terminated. The complaints allege that the breaches in fiduciary duties by the directors and officers caused damages to the Company and stockholders, including a decline in value of the Company’s common stock, increased investigatory and litigation costs, and exposure to civil liability as a result of a pending securities fraud class action suit. Plaintiffs bring the derivative actions to recover damages against the directors and officers for the benefit of the Company, and to require the Company to reform and improve its corporate governance and internal procedures. With respect to Breitman, the Company and plaintiffs filed a Joint Stipulation to Stay the matter pending the outcome of a related putative class action lawsuit, described below. With respect to Kops, the Superior Court of New Jersey stayed the matter until October 27, 2014. The defendants believe that the allegations in the derivative complaints are without merit and intend to defend the lawsuits vigorously; however, there can be no assurance regarding the ultimate outcome of these lawsuits.
	A putative class action lawsuit, styled Nasyrova v. Immunomedics, Inc., was filed on February 27, 2014 in the United States District Court for the District of New Jersey. The lawsuit alleges that the Company and certain of its current and former officers and directors failed to disclose and/or made material misstatements in the Company’s public filings relating to the termination of the Nycomed Agreement. In particular, the complaint alleges that defendants failed to make timely disclosure concerning a dispute concerning a delay in the development of veltuzumab. On October 9, 2013, the Company announced that the Nycomed Agreement was terminated. The complaint alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. On June 24, 2014, the District Court entered an order appointing John Nett as lead plaintiff and The Rosen Firm, P.A. as lead counsel. Lead plaintiff and lead counsel thereafter filed an Amended Class Action Complaint on August 8, 2014. The defendants believe that the allegations in the class action complaint are without merit and intend to defend the lawsuit vigorously; however, there can be no assurance regarding the ultimate outcome of this lawsuit.
	Immunomedics is also a party to various claims and litigation arising in the normal course of business, which includes some or all of certain of its patents. While it is not possible to determine the outcome of these matters, the Company believes that the resolution of all such matters will not have a material adverse effect on its consolidated financial position or liquidity, but could possibly be material to its consolidated results of operations in any one accounting period.
	Arbitration Settlement:
	On April 15, 2009, the Company initiated an arbitration proceeding before the Financial Industry Regulatory Authority (“FINRA”) against its former investment advisor/broker-dealer, Banc of America Investment Services, Inc., and Banc of America Securities, LLC, relating to its prior investment in certain securities. On March 27, 2013, the Company reached a settlement in such matter. Pursuant to the settlement, the Company received a gross settlement amount of $18.0 million, dismissed the proceeding with prejudice, and together with the broker-dealer, released each other from all claims and liabilities arising out of the arbitration. The Company received the net amount of approximately $16.7 million after payment of expenses and legal fees.

Geographic_Segments

Geographic Segments	12 Months Ended
	Jun. 30, 2014
Segment Reporting [Abstract]	'
Geographic Segments	'
	13	Geographic Segments
	Immunomedics manages its operations as one line of business of researching, developing, manufacturing and marketing biopharmaceutical products, particularly antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, and it currently reports as a single industry segment.
	The following table presents financial information based on the geographic location of the facilities of Immunomedics as of and for the years ended (in thousands):
			June 30, 2014
			United States			Europe			Total
	Total assets		$	44,284		$	2,560		$	46,844
	Property and equipment, net			1,895			—			1,895
	Revenues			5,947			3,095			9,042
	(Loss) before income tax expense			(35,452	)		(71	)		(35,523	)
			30-Jun-13
			United States			Europe			Total
	Total assets		$	45,552		$	2,375		$	47,927
	Property and equipment, net			2,087			—			2,087
	Revenues			2,011			2,951			4,962
	(Loss) income before income tax expense			(11,630	)		188			(11,442	)
			30-Jun-12
			United States			Europe			Total
	Total assets		$	35,570		$	3,065		$	38,635
	Property and equipment, net			2,528			—			2,528
	Revenues			29,248			3,486			32,734
	Income before income tax expense			1,149			325			1,474

Defined_Contribution_Plans

Defined Contribution Plans	12 Months Ended
	Jun. 30, 2014
Compensation And Retirement Disclosure [Abstract]	'
Defined Contribution Plans	'
	14	Defined Contribution Plans
	U.S. employees are eligible to participate in the Company’s 401(k) plan, while employees in international locations are eligible to participate in other defined contribution plans. Aggregate Company contributions to its benefit plans totaled approximately $96 thousand, $98 thousand and $95 thousand for the years ended June 30, 2014, 2013 and 2012, respectively.

Subsequent_Event

Subsequent Event	12 Months Ended
	Jun. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Event	'
	15	Subsequent Event
	Effective July 1, 2014, the Company entered into the Fifth Amended and Restated Employment Agreement with Cynthia L. Sullivan pertaining to Ms. Sullivan’s service to the Company as the Company’s President and Chief Executive Officer.
	The Amended and Restated Sullivan Agreement will continue, unless earlier terminated by the parties, until July 1, 2017. Ms. Sullivan’s current annual base salary under the Amended Sullivan Agreement is $0.6 million, which shall be reviewed annually for appropriate increases by the Board or the Compensation Committee. Ms. Sullivan is also eligible to participate in the Company’s incentive compensation plan in place for its senior level executives. Ms. Sullivan’s annual bonus target is 50% of her base salary, subject to achievement of performance goals established by the Compensation Committee, with a potential payout from 0 to 150% of the target amount. Ms. Sullivan will also be eligible to receive equity compensation awards under the Company’s 2006 Stock Incentive Plan, or any such successor equity compensation plan as may be in place from time to time.

Quarterly_Results_of_Operation

Quarterly Results of Operations	12 Months Ended
	Jun. 30, 2014
Quarterly Financial Information Disclosure [Abstract]	'
Quarterly Results of Operations	'
	16	Quarterly Results of Operations (Unaudited)
	The following table present summarized unaudited quarterly financial data:
			Three Months Ended
			June 30,			March  31,			December  31,			September  30,
			2014			2014			2013			2013
			(In thousands, except for per share amounts)
	Consolidated Statements of Comprehensive Loss Data:
	Revenues		$	1,188		$	1,154		$	1,202		$	5,498
	Net loss attributable to Immunomedics, Inc.			(11,847	)		(9,506	)		(8,873	)		(5,201	)
	Loss per common share attributable to Immunomedics Inc. – basic and diluted		$	(0.13	)	$	(0.11	)	$	(0.12	)	$	(0.06	)
	Weighted average shares used to calculate loss per common share – basic and diluted			89,084			83,340			83,175			82,947
			Three Months Ended
			June  30,			March  31,			December  31,			September  30,
			2013			2013			2012			2012
			(In thousands, except for per share amounts)
	Consolidated Statements of Comprehensive Loss Data:
	Revenues		$	1,363		$	1,736		$	812		$	1,051
	Net (loss) income attributable to Immunomedics, Inc.			(7,683	)		8,609			(5,166	)		(7,141	)
	(Loss) income per common share attributable to Immunomedics Inc. – basic		$	(0.09	)	$	0.11		$	(0.07	)	$	(0.10	)
	(Loss) income per common share attributable to Immunomedics Inc.– fully diluted		$	(0.09	)	$	0.11		$	(0.07	)	$	(0.10	)
	Weighted average shares used to calculate loss per common share – basic			82,737			78,196			75,671			75,610
	Weighted average shares used to calculate loss per common share – diluted			82,737			78,447			75,671			75,610

Schedule_II_Valuation_and_Qual

Schedule II - Valuation and Qualifying Reserves	12 Months Ended
	Jun. 30, 2014
Valuation And Qualifying Accounts [Abstract]	'
Schedule II - Valuation and Qualifying Reserves	'
	Immunomedics, Inc. and Subsidiaries
	Schedule II – Valuation and Qualifying Reserves
	For the Fiscal Years Ended June 30, 2014, 2013 and 2012
	Allowance for Doubtful Accounts
	Year ended:	Balance at			Changes to			Credits to		Other		Balance at
		Beginning			Reserve			Expense		Charges		End of
		of Year										Year
	30-Jun-12	$	(32,012	)	$	(22,797	)	$	—	$	—	$	(54,809	)
	30-Jun-13	$	(54,809	)	$	5,544		$	—	$	—	$	(49,265	)
	30-Jun-14	$	(49,265	)	$	(39,344	)	$	—	$	—	$	(88,609	)

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Principles of Consolidation and Presentation	'
	Principles of Consolidation and Presentation
	The consolidated financial statements include the accounts of Immunomedics and its majority-owned subsidiaries. Noncontrolling interests in consolidated subsidiaries in the consolidated balance sheets represent minority stockholders’ proportionate share of the equity (deficit) in such subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reported period. Actual results could differ from those estimates. The Company’s significant estimates and assumptions relate to revenue recognition, allowance for doubtful accounts, valuation of inventory and property and equipment, useful lives of property and equipment, accrued liabilities, stock compensation expenses, income tax uncertainties and other contingencies.
Foreign Currencies	'
	Foreign Currencies
	For subsidiaries outside of the United States that operate in a local currency environment, income and expense items are translated to United States dollars at the monthly average rates of exchange prevailing during the year, assets and liabilities are translated at year-end exchange rates and equity accounts are translated at historical exchange rates. Translation adjustments are accumulated in a separate component of stockholders’ equity in the Consolidated Balance Sheets and the Consolidated Statements of Changes in Stockholders’ Equity and are included in the determination of comprehensive (loss) income in the Consolidated Statements of Comprehensive (Loss) Income. Transaction gains and losses are included in the determination of net (loss) income in the Consolidated Statements of Comprehensive (Loss) Income. As of June 30, 2014 and 2013, the cumulative unrealized foreign currency translation gain included in accumulated other comprehensive income was approximately $0.3 million and $0.2 million, respectively.
Marketable securities	'
	Marketable securities
	Marketable securities, all of which are available-for-sale, consist of corporate debt securities and municipal bonds. Marketable securities are carried at fair value, with unrealized gains and losses, net of related income taxes, reported as accumulated other comprehensive income, except for losses from impairments which are determined to be other-than-temporary. Realized gains and losses, and declines in value judged to be other-than-temporary on available-for-sale securities are included in the determination of net (loss) income and are included in interest and other income (net), at which time the average cost basis of these securities are adjusted to fair value. Fair values are based on quoted market prices at the reporting date. Interest and dividends on available-for-sale securities are included interest and other income (net).
Accounts Receivable	'
	Accounts Receivable
	Credit is extended to customers based upon an evaluation of the customer’s financial condition. Accounts receivable are recorded at net realizable value. The Company utilizes a specific identification accounts receivable reserve methodology based on a review of outstanding balances and previous activities to determine the allowance for doubtful accounts. The Company charges off uncollectible receivables at the time the Company determines the receivable is no longer collectible. The Company does not require collateral or other security to support financial instruments subject to credit risk.
Concentration of Credit Risk	'
	Concentration of Credit Risk
	Cash, cash equivalents and marketable securities are financial instruments that potentially subject the Company to concentration of credit risk. Immunomedics periodically invests its cash in debt instruments of banks and financial institutions with strong credit ratings. Immunomedics has established guidelines relative to diversification and maturities that are designed to help ensure safety and liquidity. These guidelines are periodically reviewed to take advantage of trends in yields and interest rates.
Estimated Fair Value of Financial Instruments	'
	Estimated Fair Value of Financial Instruments
	The Company has categorized its financial assets, based on the priority of the inputs to the valuation technique, into a three-level fair value hierarchy as set forth below. The Company does not have any financial liabilities that are required to be measured at fair value on a recurring basis. If the inputs used to measure the financial instruments fall within different levels of the hierarchy, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.
	Financial assets recorded on the consolidated balance sheets as of June 30, 2014 and 2013 are categorized based on the inputs to the valuation techniques as follows (in thousands):
		•		Level 1 – Financial assets whose values are based on unadjusted quoted prices for identical assets or liabilities in an active market which the Company has the ability to access at the measurement date (examples include active exchange-traded equity securities and most U.S. Government and agency securities).
		•		Level 2 – Financial assets whose value are based on quoted market prices in markets where trading occurs infrequently or whose values are based on quoted prices of instruments with similar attributes in active markets.
		•		Level 3 – Financial assets whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. These inputs reflect management’s own assumptions about the assumptions a market participant would use in pricing the asset.
			Level 1			Level 2		Level 3		Total
	June 30, 2014
	Money Market Funds		$	367		$	—	$	—	$	367
	Marketable Securities:
	U.S. Treasury Bonds			8,537			—		—		8,537
	U.S. Government Sponsored Agencies			7,457			—		—		7,457
	Corporate Debt Securities			18,877			—		—		18,877
	Total		$	35,238		$	—	$	—	$	35,238
	June 30, 2013
	Money Market Funds		$	38,327		$	—	$	—	$	38,327
	Total		$	38,327		$	—	$	—	$	38,327
	The money market funds noted above are included in cash and cash equivalents in the consolidated balance sheets. We recognize transfers between levels of the fair value hierarchy as of the date of the transaction. There were no transfers within the hierarchy during the fiscal years 2014 and 2013.
Inventory	'
	Inventory
	Inventory, which consists of the finished product and work in process of LeukoScan, is stated at the lower of cost (on a first-in, first-out basis) or market, and includes materials, labor and manufacturing overhead.
Property and Equipment and Impairment of Assets	'
	Property and Equipment and Impairment of Assets
	Property and equipment are stated at cost and are depreciated on a straight-line basis over the estimated useful lives (5-10 years) of the respective assets. Leasehold improvements are capitalized and amortized over the lesser of the remaining life of the lease or the estimated useful life of the asset. Immunomedics reviews long-lived assets for impairment whenever events or changes in business circumstances occur that indicate that the carrying amount of the assets may not be recoverable. Immunomedics assesses the recoverability of long-lived assets held and to be used based on undiscounted cash flows, and measures the impairment, if any, using discounted cash flows. To date the Company has not taken any impairment charges on property and equipment.
Life Insurance Policies	'
	Life Insurance Policies
	The Company has life insurance policies on Dr. David M. Goldenberg, the Company’s Chief Medical Officer and Chief Scientific Officer, which are for the benefit of the Company. When the Company is the beneficiary of the policy, and there are no other contractual arrangements between the Company and Dr. Goldenberg, the Company recognizes the amount that could be realized under the insurance arrangement as an asset in the Consolidated Balance Sheets.
Revenue Recognition	'
	Revenue Recognition
	The Company has accounted for revenue arrangements that include multiple deliverables as a separate unit of accounting if both of the following criteria are met: a) the delivered item has value to the customer on a standalone basis, and b) if the right of return exists, delivery of the undelivered items is considered probable and substantially in the control of the vendor. If these criteria are not met, the revenue elements must be considered a single unit of accounting for purposes of revenue recognition. The Company allocates revenue consideration, excluding contingent consideration, based on the relative selling prices of the separate units of accounting contained within an arrangement containing multiple deliverables. Relative selling prices are determined using vendor specific objective evidence, if it exists; otherwise third-party evidence or the Company’s best estimate of selling price is used for each deliverable.
	Payments received under contracts to fund certain research activities are recognized as revenue in the period in which the research activities are performed. Payments received in advance that are related to future performance are deferred and recognized as revenue when the research projects are performed. Upfront nonrefundable fees associated with license and development agreements where the Company has continuing involvement in the agreement are recorded as deferred revenue and recognized over the estimated service period. The Company estimates the period of continuing involvement based on the best evidential matter available at each reporting period. If the estimated service period is subsequently modified, the period over which the upfront fee is recognized is modified accordingly on a prospective basis.
	In order to determine the revenue recognition for contingent milestones, the Company evaluates the contingent milestones using the criteria as provided by the Financial Accounting Standards Boards (“FASB”) guidance on the milestone method of revenue recognition, as explained in ASU 2010-17, “Milestone Method of Revenue Recognition”, at the inception of a collaboration agreement. The criteria requires that (i) the Company determines if the milestone is commensurate with either its performance to achieve the milestone or the enhancement of value resulting from the Company’s activities to achieve the milestone, (ii) the milestone be related to past performance, and (iii) the milestone be reasonable relative to all deliverable and payment terms of the collaboration arrangement. If these criteria are met then the contingent milestones can be considered as substantive milestones and will be recognized as revenue in the period that the milestone is achieved. Royalties are recognized as earned in accordance with the terms of various research and collaboration agreements.
	Revenue from the sale of diagnostic products is recorded when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed and determinable or collectability is reasonably assured. Allowances, if any, are established for uncollectible amounts, estimated product returns and discounts. Since allowances are recorded based on management’s estimates, actual amounts may be different in the future.
Research and Development Costs	'
	Research and Development Costs
	Research and development costs are expensed as incurred. Costs incurred for clinical trials for patients and investigators are expensed as services are performed in accordance with the agreements in place with the institutions.
Reimbursement of Research and Development Costs	'
	Reimbursement of Research and Development Costs
	Reimbursement toward research and development costs under collaboration agreements are included as a reduction of research and development expenses. The Company records these reimbursements as a reduction of research and development expenses as the Company’s partner in the collaboration agreement has the financial risks and responsibility for conducting these research and development activities.
Manufacturing Costs	'
	Manufacturing Costs
	Manufacturing costs incurred in relation to the development of materials produced in order to fulfill contractual obligations are deferred and are recorded in other current assets until the product is delivered in accordance with the terms of the agreement.
Income Taxes	'
	Income Taxes
	The Company uses the asset and liability method to account for income taxes, including the recognition of deferred tax assets and deferred tax liabilities for the anticipated future tax consequences attributable to differences between financial statements amounts and their respective tax bases. The Company reviews its deferred tax assets for recovery. A valuation allowance is established when the Company believes that it is more likely than not that its deferred tax assets will not be realized. Changes in valuation allowances from period to period are included in the Company’s tax provision in the period of change.
	The Company does not have an accrual for uncertain tax positions as of June 30, 2014 or 2013. The U.S. Federal statute of limitation remains open for the fiscal years 2009 onward. The Company’s tax returns filed in foreign jurisdictions remain open for the fiscal years 2010 onward. State income tax returns are generally subject to examination for a period of 3-5 years after filing of the respective return. The Company conducts business and files tax returns in New Jersey.
Net (Loss) Income Per Share Allocable to Common Stockholders	'
	Net (Loss) Income Per Share Allocable to Common Stockholders
	Basic net (loss) income per share is based upon the number of weighted average number of shares of common stock and vested restricted shares outstanding. Diluted net income per share is based upon the weighted average number of shares of common stock and dilutive potential shares of common stock outstanding. During fiscal years 2014 and 2013, no potential shares of common stock were included in the calculation since their affect would be anti-dilutive due to the operating losses. For fiscal year 2012, diluted net income per share is based upon the weighted average number of shares of common stock and dilutive potential shares of common stock outstanding. Potential shares of common stock that result from the assumed exercise of outstanding stock options and warrant shares, with exercise prices less than the average market price of the Company’s common stock are calculated under the treasury stock method. All other outstanding stock options and warrant shares have been excluded from the calculation.
Comprehensive (Loss) Income	'
	Comprehensive (Loss) Income
	Comprehensive (loss) income consists of consolidated net (loss) income, net unrealized loss on securities available for sale and foreign currency exchange translation adjustments and is presented in the Consolidated Statements of Comprehensive (Loss) Income.
Stock-Based Compensation	'
	Stock-Based Compensation
	The Company’s 2006 Stock Incentive Plan (the “Plan”) permits the grant of options and shares to its employees and outside directors for up to eight million shares of common stock. A summary of this plan is provided in Note 7. The Company believes that such awards better align the interests of its employees with those of its shareholders. Option awards are generally granted with an exercise price equal to the market price of the Company’s stock at the date of grant; those option awards generally vest based on four years of continuous service and have seven year contractual terms. Certain options provide for accelerated vesting if there is a change in control (as defined in the Plan).
	The fair value of each option granted during the years ended June 30, 2014, 2013 and 2012 is estimated on the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions in the following table:
			Years ended June 30,
			2014		2013	2012
	Expected dividend yield		0%		0%	0%
	Expected option term (years)		3.85		5.35	5.32
	Expected stock price volatility		65%		69%	80%
	Risk-free interest rate		0.03% - 1.79%		0.98% - 1.84%	1.01% - 2.46%
	The weighted average fair value at the date of grant for options granted during the years ended June 30, 2014, 2013 and 2012 were $1.91, $2.12 and $2.23 per share, respectively. The Company uses historical data to estimate forfeitures. The expected term of options granted represents the period of time that options granted are expected to be outstanding. Expected stock price volatility was calculated based on the Company’s daily stock trading history. The weighted average of the expected option term declined to 3.85 years for year ended June 30, 2014, as a result of the issuance of short-term options to the former chief financial officer. Aside from these stock options the expected option term for other stock options granted during the year ended June 30, 2014 was 5.1 years. The risk-free rate for periods within the expected term of the option is based on the U.S. Treasury yield curve in effect at the time of grant. The lower risk-free interest rate results from the short-term rate for the stock options granted to the former chief financial officer.
	As of June 30, 2014, the Company has 1,838,587 non-vested options and restricted stock shares outstanding. As of June 30, 2014, 2013 and 2012 there was $4.1 million, $3.6 million and $3.3 million, respectively, of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the Plan. That cost is being recognized over a weighted-average period of 2.52 years. The weighted average remaining contractual terms of the exercisable shares is 2.72 years and 2.59 years as of June 30, 2014 and 2013, respectively.
Financial Instruments	'
	Financial Instruments
	The carrying amounts of cash and cash equivalents, other current assets and current liabilities approximate fair value due to the short-term maturity of these instruments. The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents.
Insurance Proceeds	'
	Insurance Proceeds
	Insurance proceeds totaling $2.6 million were received during the fiscal year 2013 as a result of insurance claims from an equipment failure during the 2011 fiscal year. A cash payment for a business interruption insurance claim of $2.5 million was received, which had resulted from the equipment failure that had limited the production of materials necessary for certain research & product development. There was no such claim for fiscal year 2012. In addition, for fiscal year ended June 30, 2013 proceeds of $0.1 million was also recorded from a property claim regarding the same equipment failure. The proceeds received from these claims are classified as a separate other income component in the Consolidated Statement of Comprehensive (Loss) Income.
Recently Issued Accounting Pronouncements	'
	Recently Issued Accounting Pronouncements
	In June 2014, the FASB issued Accounting Standard Update (“ASU”) 2014-012, “Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period”. This guidance clarifies that awards with these provisions should be treated as performance conditions that affect vesting, and do not impact the award’s estimated grant-date fair value. The amendments in this update are effective for annual reporting periods beginning after December 31, 2015, including interim periods, and early application is permitted. The Company is assessing ASU 2014-012’s impact and will adopt it when effective.
	In June 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers”. This ASU was initiated as a joint project by the FASB and the International Accounting Standards Board (“IASB”) to clarify the principles for recognizing revenue and to develop a common revenue standard for U.S. GAAP and IFRS. For a public company, the amendments in this update are effective for annual reporting periods beginning after December 15, 2016, including interim periods, and early application is not permitted for public companies. The Company is assessing ASU 2014-09’s impact and will adopt it when effective.
	In July 2013, the FASB issued ASU 2013-11, “Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carry-forward, a Similar Tax Loss, or a Tax Credit Carry-forward Exists”. This ASU will eliminate the diversity in practice in presentation of unrecognized tax benefits when a net operating loss carry-forward, a similar tax loss, or a tax credit carry-forward exists at the reporting date. This new guidance requires the netting of unrecognized tax benefits against a deferred tax asset for a loss or other carry-forward that would apply in settlement of the uncertain tax positions. Under the new guidance, unrecognized tax benefits will be netted against all available same-jurisdiction loss or other tax carry-forward that would be utilized, rather than only against carryforwards that are created by the unrecognized tax benefits. This guidance is effective prospectively, but allows optional retrospective adoption (for all periods presented), for reporting periods beginning after December 15, 2013. As this guidance relates to presentation only, the adoption of this guidance did not impact the Company’s financial statements.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Financial Assets Recorded on Consolidated Balance Sheets	'
	Financial assets recorded on the consolidated balance sheets as of June 30, 2014 and 2013 are categorized based on the inputs to the valuation techniques as follows (in thousands):
		•		Level 1 – Financial assets whose values are based on unadjusted quoted prices for identical assets or liabilities in an active market which the Company has the ability to access at the measurement date (examples include active exchange-traded equity securities and most U.S. Government and agency securities).
		•		Level 2 – Financial assets whose value are based on quoted market prices in markets where trading occurs infrequently or whose values are based on quoted prices of instruments with similar attributes in active markets.
		•		Level 3 – Financial assets whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. These inputs reflect management’s own assumptions about the assumptions a market participant would use in pricing the asset.
			Level 1			Level 2		Level 3		Total
	June 30, 2014
	Money Market Funds		$	367		$	—	$	—	$	367
	Marketable Securities:
	U.S. Treasury Bonds			8,537			—		—		8,537
	U.S. Government Sponsored Agencies			7,457			—		—		7,457
	Corporate Debt Securities			18,877			—		—		18,877
	Total		$	35,238		$	—	$	—	$	35,238
	June 30, 2013
	Money Market Funds		$	38,327		$	—	$	—	$	38,327
	Total		$	38,327		$	—	$	—	$	38,327
Schedule of Options Weighted-Average Assumptions	'
	The fair value of each option granted during the years ended June 30, 2014, 2013 and 2012 is estimated on the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions in the following table:
			Years ended June 30,
			2014		2013	2012
	Expected dividend yield		0%		0%	0%
	Expected option term (years)		3.85		5.35	5.32
	Expected stock price volatility		65%		69%	80%
	Risk-free interest rate		0.03% - 1.79%		0.98% - 1.84%	1.01% - 2.46%

Marketable_Securities_Tables

Marketable Securities (Tables)	12 Months Ended
	Jun. 30, 2014
Investments Debt And Equity Securities [Abstract]	'
Components of Marketable Securities	'
	Marketable securities at June 30, 2014 consist of the following (in thousands):
		Amortized		Gross		Gross			Fair Value
		Cost		Unrealized		Unrealized
				Gain		(Loss)
	June 30, 2014
	U.S. Treasury Bonds	$	8,537	$	1	$	(1	)	$	8,537
	U.S. Government Sponsored Agencies		7,458		—		(1	)		7,457
	Corporate Debt Securities		18,876		12		(11	)		18,877
		$	34,871	$	13	$	(13	)	$	34,871
Maturities of Debt Securities Classified as Available-for-Sale	'
	Maturities of debt securities classified as available-for-sale were as follows at June 30, 2014 (in thousands):
		Fair Value		Net Carrying
				Amount
	Due within one year	$	25,336	$	25,449
	Due after one year through five years		9,535		9,603
		$	34,871	$	35,052

Inventory_Tables

Inventory (Tables)	12 Months Ended
	Jun. 30, 2014
Inventory Disclosure [Abstract]	'
Schedule of Inventory	'
	Inventory consisted of the following at June 30 (in thousands):
		2014		2013
	Work in process	$	—	$	914
	Finished goods		779		116
	Total	$	779	$	1,030

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Jun. 30, 2014
Property Plant And Equipment [Abstract]	'
Summary of Property and Equipment	'
	Property and equipment consisted of the following at June 30 (in thousands):
		2014			2013
	Machinery and equipment	$	7,917		$	7,766
	Leasehold improvements		18,125			18,087
	Furniture and fixtures		933			933
	Computer equipment		2,233			2,044
			29,208			28,830
	Accumulated depreciation and amortization		(27,313	)		(26,743	)
		$	1,895		$	2,087

Accounts_Payable_and_Accrued_E1

Accounts Payable and Accrued Expenses (Tables)	12 Months Ended
	Jun. 30, 2014
Payables And Accruals [Abstract]	'
Summary of Accounts Payable and Accrued Expenses	'
	Accounts payable and accrued expenses consisted of the following at June 30 (in thousands):
		2014		2013
	Trade accounts payable	$	2,366	$	980
	Clinical trial accruals		1,981		1,543
	Legal expenses		690		165
	Executive bonus		688		676
	Miscellaneous other current liabilities		519		587
		$	6,244	$	3,951

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	12 Months Ended
	Jun. 30, 2014
Equity [Abstract]	'
Summary of Options	'
	Information concerning options for the years ended June 30, 2014, 2013 and 2012 is summarized as follows:
			Number of Shares									Weighted Average Price
			2014			2013			2012			2014		2013		2012
	Options outstanding, beginning of year			5,726,874			5,799,100			6,471,975		$	3.3	$	3.72	$	4.92
	Options granted			1,216,729			759,900			349,000		$	4.79	$	3.59	$	3.4
	Options exercised			(535,730	)		(88,594	)		(59,126	)	$	3.36	$	3	$	2.91
	Options cancelled or forfeited			(1,099,256	)		(743,532	)		(962,749	)	$	4.35	$	6.96	$	11.7
	Options outstanding, end of year			5,308,617			5,726,874			5,799,100		$	3.41	$	3.3	$	3.72
	Options exercisable, end of year			4,121,942			4,572,716			4,686,364		$	3.18	$	3.21	$	3.81
Options Outstanding Under the Plan	'
	The following table summarizes information concerning options outstanding under the Plan at June 30, 2014:
	Range of		Number			Weighted			Weighted			Number		Weighted
	exercise price		outstanding			average			average			exercisable		average
			at June 30, 2014			exercise			remaining			at June 30, 2014		exercise
						price			term (yrs.)					price
	$1.59 - 3.00			2,078,288		$	2.43			1.56			2,074,663	$	2.43
	3.01 - 5.00			2,505,448			3.68			4.14			1,671,054		3.67
	5.01 - 7.00			724,881			5.28			6.39			376,225		5.21
				5,308,617		$	3.41			3.44			4,121,942	$	3.18
Non-Vested Restricted Stock Units	'
	A summary of the Company’s non-vested restricted stock units at June 30, 2014, and changes during the year ended June 30, 2014 is presented below:
	Non-Vested Restricted Stock		Number of Awards
	Non-vested at July 1, 2013			488,575
	Restricted Unites Granted			192,168
	Performance Units Granted			389,864
	Vested/Exercised			(257,243	)
	Forfeited			(25,000	)
	Non-vested at June 30, 2014			788,364
Components of Accumulated Other Comprehensive Income	'
	The components of accumulated other comprehensive income were as follows:
			Currency			Net Unrealized Gains			Accumulated Other
			Translation			(Losses) on Available-			Comprehensive
			Adjustments			for-Sale Securities			Income
	Balance, July 1, 2011		$	394,669		$	—		$	394,669
	Change for the year			(314,508	)		—			(314,508	)
	Balance, June 30, 2012			80,161			—			80,161
	Change for the year			81,669			—			81,669
	Balance, June 30, 2013			161,830			—			161,830
	Other comprehensive income before reclassifications			100,094			7,430			107,524
	Amounts reclassified from accumulated other comprehensive income(a)			—			(7,517	)		(7,517	)
	Net current-period other comprehensive income			100,094			(87	)		100,007
	Balance, June 30, 2014		$	261,924		$	(87	)	$	261,837
	All components of accumulated other comprehensive income are net of tax, except currency translation adjustments, which exclude income taxes related to indefinite investments in foreign subsidiaries.
	(a)	For the fiscal year ended June 30, 2014, $7,517 was reclassified from accumulated other comprehensive income to interest and other income.

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	12 Months Ended
	Jun. 30, 2014
Earnings Per Share [Abstract]	'
Basic and Diluted Earnings Per Share	'
	Diluted earnings per share for the years presented do not include securities if their effect was anti-dilutive.
		2014			2013			2012
		(in thousands, except per share amounts)
	Net (loss) income attributable to Immunomedics, Inc.	$	(35,426	)	$	(11,382	)	$	1,378
	Basic earnings per share:
	Weighted average basic common shares outstanding		84,632			78,040			75,481
	Basic (loss) earnings per common share attributable to Immunomedics, Inc.	$	(0.42	)	$	(0.15	)	$	0.02
	Diluted earnings per share:
	Weighted average basic common shares outstanding		84,632			78,040			75,481
	Dilutive effect of restricted stock		—			—			82
	Dilutive effect of stock options outstanding		—			—			611
	Weighted average diluted common shares outstanding		84,632			78,040			76,174
	Diluted (loss) earnings per common share attributable to Immunomedics, Inc.	$	(0.42	)	$	(0.15	)	$	0.02
	Stock options and warrant shares excluded from the weighted average diluted common shares outstanding because their inclusion would have been anti-dilutive		6,309			6,727			5,699
	Restricted stock excluded from the weighted average diluted common shares outstanding because their inclusion would have been anti-dilutive		788			489			357

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2014
Income Tax Disclosure [Abstract]	'
Expense (Benefit) for Income Taxes	'
	The expense (benefit) for income taxes is as follows (in thousands):
		Year Ended June 30,
		2014			2013			2012
	Federal
	Current	$	—		$	(38	)	$	126
	Deferred		—			—			—
	Total Federal		—			(38	)		126
	State
	Current		1			2			2
	Deferred		—			—			—
	Total State		1			2			2
	Foreign
	Current		7			80			82
	Deferred		—			—			—
	Total Foreign		7			80			82
	Total Expense	$	8		$	44		$	210
Reconciliation of Statutory Tax Rates and Effective Tax Rates	'
	A reconciliation of the statutory tax rates and the effective tax rates for each of the years ended June 30 is as follows:
		2014			2013			2012
	Statutory rate		(34.0	%)		(34.0	%)		34	%
	State income taxes (net of Federal tax benefit)		0	%		0	%		0.3	%
	Foreign income tax		0.1	%		0.1	%		(3.2	%)
	Change in valuation allowance		27.5	%		12.1	%		(716.2	%)
	NOL expiration		0	%		24.3	%		754.5	%
	R&D tax credit expiration		0	%		(3.4	%)		(72.8	%)
	Other		6.4	%		1.3	%		17.6	%
	Effective rate		0	%		0.4	%		14.2	%
Tax Effects of Temporary Differences in Deferred Tax Assets	'
	The tax effects of temporary differences that give rise to significant portions of the Company’s deferred tax assets as of June 30, 2014 and 2013 are presented below (in thousands):
		2014			2013
	Deferred tax assets:
	NOL carry forwards	$	66,699		$	53,941
	Research and development credits		12,264			11,707
	Property and equipment		4,055			4,369
	Other		5,479			8,705
	Total		88,497			78,722
	Valuation allowance		(88,497	)		(78,722	)
	Net deferred taxes	$	—		$	—

Related_Party_Transactions_Tab

Related Party Transactions (Tables)	12 Months Ended
	Jun. 30, 2014
Related Party Transactions [Abstract]	'
Shares of IBC Pharmaceuticals, Inc.	'
	As of June 30, 2014, the shares of IBC Pharmaceuticals, Inc. were held as follows:
	Stockholder	Holdings	Percentage of Total
	Immunomedics, Inc.	5,615,124 shares of Series A Preferred Stock		73.46	%
	Third Party Investors	628,282 shares of Series B Preferred Stock		8.22	%
	David M. Goldenberg Millennium Trust	1,399,926 shares of Series C Preferred Stock		18.32	%
				100	%

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Jun. 30, 2014
Commitments And Contingencies Disclosure [Abstract]	'
Schedule of Minimum Lease Commitments for Facilities	'
	The minimum lease commitments for the non-cancelable term of the facility lease described above are as follows for fiscal years (in thousands):
	2015	$	838
	2016	$	838
	2017	$	929
	2018	$	974
	2019	$	974
	Thereafter	$	12,710

Geographic_Segments_Tables

Geographic Segments (Tables)	12 Months Ended
	Jun. 30, 2014
Segment Reporting [Abstract]	'
Financial Information Based on Geographic Location of Facilities	'
	The following table presents financial information based on the geographic location of the facilities of Immunomedics as of and for the years ended (in thousands):
		June 30, 2014
		United States			Europe			Total
	Total assets	$	44,284		$	2,560		$	46,844
	Property and equipment, net		1,895			—			1,895
	Revenues		5,947			3,095			9,042
	(Loss) before income tax expense		(35,452	)		(71	)		(35,523	)
		30-Jun-13
		United States			Europe			Total
	Total assets	$	45,552		$	2,375		$	47,927
	Property and equipment, net		2,087			—			2,087
	Revenues		2,011			2,951			4,962
	(Loss) income before income tax expense		(11,630	)		188			(11,442	)
		30-Jun-12
		United States			Europe			Total
	Total assets	$	35,570		$	3,065		$	38,635
	Property and equipment, net		2,528			—			2,528
	Revenues		29,248			3,486			32,734
	Income before income tax expense		1,149			325			1,474

Quarterly_Results_of_Operation1

Quarterly Results of Operations (Tables)	12 Months Ended
	Jun. 30, 2014
Quarterly Financial Information Disclosure [Abstract]	'
Summarized Unaudited Quarterly Financial Data	'
	The following table present summarized unaudited quarterly financial data:
		Three Months Ended
		June 30,			March  31,			December  31,			September  30,
		2014			2014			2013			2013
		(In thousands, except for per share amounts)
	Consolidated Statements of Comprehensive Loss Data:
	Revenues	$	1,188		$	1,154		$	1,202		$	5,498
	Net loss attributable to Immunomedics, Inc.		(11,847	)		(9,506	)		(8,873	)		(5,201	)
	Loss per common share attributable to Immunomedics Inc. – basic and diluted	$	(0.13	)	$	(0.11	)	$	(0.12	)	$	(0.06	)
	Weighted average shares used to calculate loss per common share – basic and diluted		89,084			83,340			83,175			82,947
		Three Months Ended
		June  30,			March  31,			December  31,			September  30,
		2013			2013			2012			2012
		(In thousands, except for per share amounts)
	Consolidated Statements of Comprehensive Loss Data:
	Revenues	$	1,363		$	1,736		$	812		$	1,051
	Net (loss) income attributable to Immunomedics, Inc.		(7,683	)		8,609			(5,166	)		(7,141	)
	(Loss) income per common share attributable to Immunomedics Inc. – basic	$	(0.09	)	$	0.11		$	(0.07	)	$	(0.10	)
	(Loss) income per common share attributable to Immunomedics Inc.– fully diluted	$	(0.09	)	$	0.11		$	(0.07	)	$	(0.10	)
	Weighted average shares used to calculate loss per common share – basic		82,737			78,196			75,671			75,610
	Weighted average shares used to calculate loss per common share – diluted		82,737			78,447			75,671			75,610

Business_Overview_Additional_I

Business Overview - Additional Information (Detail) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2011
	Subsidiary
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]	'	'	'	'
Number of subsidiaries	2	'	'	'
Cash, cash equivalents and marketable securities	$41,800,000	'	'	'
Cash and cash equivalents	6,961,494	41,326,000	32,838,096	27,097,610
Scenario, Forecast [Member]	'	'	'	'
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]	'	'	'	'
Cash and cash equivalents	$41,000,000	'	'	'

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Business Interruption Loss [Line Items]	'	'	'
Cumulative unrealized foreign currency translation gain included in accumulated other comprehensive income	$300,000	$200,000	'
Impairment charges on property and equipment	0	'	'
Potential shares of common stock	0	0	'
Vesting period of stock options	'4 years	'	'
Contractual terms of stock option	'7 years	'	'
Weighted average fair value at the date of grant for options granted	$1.91	$2.12	$2.23
Expected option term (years)	'3 years 10 months 6 days	'5 years 4 months 6 days	'5 years 3 months 26 days
Non-vested options and restricted stock shares outstanding	1,838,587	'	'
Unrecognized compensation cost related to non-vested share-based compensation arrangements	4,100,000	3,600,000	3,300,000
Cost recognized over a weighted-average period	'2 years 6 months 7 days	'	'
Weighted average of remaining contractual terms of the exercisable shares	'2 years 8 months 19 days	'2 years 7 months 2 days	'
Highly liquid investments, original maturity period	'3 months	'	'
Insurance proceeds received	0	2,637,879	0
Business Interruption [Member]	'	'	'
Business Interruption Loss [Line Items]	'	'	'
Insurance proceeds received	'	2,500,000	0
Property Damage Claims [Member]	'	'	'
Business Interruption Loss [Line Items]	'	'	'
Insurance proceeds received	'	$100,000	'
Other Stock Options [Member]	'	'	'
Business Interruption Loss [Line Items]	'	'	'
Expected option term (years)	'5 years 1 month 6 days	'	'
2006 Stock Incentive Plan [Member]	'	'	'
Business Interruption Loss [Line Items]	'	'	'
Stock Incentive Plan permits the grant of options and shares to its employees and outside directors	8,000,000	'	'
Maximum [Member]	'	'	'
Business Interruption Loss [Line Items]	'	'	'
Property and equipment estimated useful lives	'10 years	'	'
State income tax returns examination period	'5 years	'	'
Minimum [Member]	'	'	'
Business Interruption Loss [Line Items]	'	'	'
Property and equipment estimated useful lives	'5 years	'	'
State income tax returns examination period	'3 years	'	'

Summary_of_Significant_Account4

Summary of Significant Accounting Policies - Financial Assets Recorded on Consolidated Balance Sheets (Detail) (USD $)	Jun. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	$35,238	$38,327
Money Market Funds [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	367	38,327
U.S. Treasury Bonds [Member] | Marketable Securities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	8,537	'
U.S. Government Sponsored Agencies [Member] | Marketable Securities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	7,457	'
Corporate Debt Securities [Member] | Marketable Securities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	18,877	'
Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	35,238	38,327
Level 1 [Member] | Money Market Funds [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	367	38,327
Level 1 [Member] | U.S. Treasury Bonds [Member] | Marketable Securities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	8,537	'
Level 1 [Member] | U.S. Government Sponsored Agencies [Member] | Marketable Securities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	7,457	'
Level 1 [Member] | Corporate Debt Securities [Member] | Marketable Securities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial assets	$18,877	'

Summary_of_Significant_Account5

Summary of Significant Accounting Policies - Schedule of Options Weighted-Average Assumptions (Detail)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'	'	'
Expected dividend yield	0.00%	0.00%	0.00%
Expected option term (years)	'3 years 10 months 6 days	'5 years 4 months 6 days	'5 years 3 months 26 days
Expected stock price volatility	65.00%	69.00%	80.00%
Risk-free interest rate, minimum	0.03%	0.98%	1.01%
Risk-free interest rate, maximum	1.79%	1.84%	2.46%

Marketable_Securities_Addition

Marketable Securities - Additional Information (Detail) (USD $)	12 Months Ended
	Jun. 30, 2014
Investments Debt And Equity Securities [Abstract]	'
Cash and cash equivalents investments into debt securities and municipal bonds	$46,300,000
Debt securities and municipal bonds either matured or sold	$11,431,661

Marketable_Securities_Componen

Marketable Securities - Components of Marketable Securities (Detail) (USD $)	Jun. 30, 2014
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities [Line Items]	'
Amortized Cost	$34,871
Gross Unrealized Gain	13
Gross Unrealized (Loss)	-13
Fair Value	34,871
U.S. Treasury Bonds [Member]	'
Schedule of Available-for-sale Securities [Line Items]	'
Amortized Cost	8,537
Gross Unrealized Gain	1
Gross Unrealized (Loss)	-1
Fair Value	8,537
U.S. Government Sponsored Agencies [Member]	'
Schedule of Available-for-sale Securities [Line Items]	'
Amortized Cost	7,458
Gross Unrealized (Loss)	-1
Fair Value	7,457
Corporate Debt Securities [Member]	'
Schedule of Available-for-sale Securities [Line Items]	'
Amortized Cost	18,876
Gross Unrealized Gain	12
Gross Unrealized (Loss)	-11
Fair Value	$18,877

Marketable_Securities_Maturiti

Marketable Securities - Maturities of Debt Securities Classified as Available-for-Sale (Detail) (USD $)	Jun. 30, 2014
In Thousands, unless otherwise specified
Investments Debt And Equity Securities [Abstract]	'
Fair Value, Due within one year	$25,336
Fair Value, Due after one year through five years	9,535
Fair Value	34,871
Net Carrying Amount, Due within one year	25,449
Net Carrying Amount, Due after one year through five years	9,603
Net Carrying Amount	$35,052

Inventory_Schedule_of_Inventor

Inventory - Schedule of Inventory (Detail) (USD $)	Jun. 30, 2014	Jun. 30, 2013
Inventory Disclosure [Abstract]	'	'
Work in process	'	$914,000
Finished goods	779,000	116,000
Total	$778,989	$1,030,480

Property_and_Equipment_Summary

Property and Equipment - Summary of Property and Equipment (Detail) (USD $)	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Property, Plant and Equipment [Line Items]	'	'	'
Property and equipment, gross	$29,208,000	$28,830,000	'
Accumulated depreciation and amortization	-27,313,000	-26,743,000	'
Property and equipment, net	1,895,475	2,086,911	2,528,000
Machinery and equipment [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property and equipment, gross	7,917,000	7,766,000	'
Leasehold improvements [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property and equipment, gross	18,125,000	18,087,000	'
Furniture and fixtures [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property and equipment, gross	933,000	933,000	'
Computer equipment [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property and equipment, gross	$2,233,000	$2,044,000	'

Property_and_Equipment_Additio

Property and Equipment - Additional Information (Detail) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Property Plant And Equipment Useful Life And Values [Abstract]	'	'	'
Depreciation and amortization expense	$569,442	$1,036,035	$1,496,783

Accounts_Payable_and_Accrued_E2

Accounts Payable and Accrued Expenses - Summary of Accounts Payable and Accrued Expenses (Detail) (USD $)	Jun. 30, 2014	Jun. 30, 2013
Payables And Accruals [Abstract]	'	'
Trade accounts payable	$2,366,000	$980,000
Clinical trial accruals	1,981,000	1,543,000
Legal expenses	690,000	165,000
Executive bonus	688,000	676,000
Miscellaneous other current liabilities	519,000	587,000
Accounts payable and accrued expenses	$6,244,105	$3,950,866

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)	0 Months Ended	1 Months Ended	12 Months Ended
	31-May-14	Feb. 28, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012	31-May-14	Aug. 16, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'
Preferred stock, shares authorized	'	'	10,000,000	10,000,000	'	'	'
Preferred stock, par value	'	'	$0.01	$0.01	'	'	'
Preferred stock, shares outstanding	'	'	0	0	0	'	'
Number of shares of common stock sold	'	7,000,000	93,113,480	82,841,123	'	9,546,474	'
Public offering price of common stock, per share	'	$2.30	$0.01	$0.01	'	$3.35	'
Net proceeds to the company from issuance of common stock	$29,800,000	$14,800,000	$29,809,448	$14,785,408	'	'	'
Stock options available for future grant	'	'	3,830,719	'	'	'	'
Performance Units vesting period	'	'	'4 years	'	'	'	'
Contractual terms of stock option	'	'	'7 years	'	'	'	'
Stock-based compensation expense	'	'	2,886,318	2,018,494	1,961,561	'	'
Stock-based compensation expense related stock options	'	'	1,500,000	1,500,000	1,500,000	'	'
Aggregate intrinsic value of outstanding stock options	'	'	3,000,000	12,300,000	'	'	'
Aggregate intrinsic value of common stock	'	'	$3.65	$5.44	'	'	'
Total intrinsic value of options exercised	'	'	800,000	100,000	33,000	'	'
Restricted stock units	'	'	'	'	'	'	136,452
Restricted stock units, market price	'	'	$3.18	'	'	'	'
Unrecognized compensation costs related to non-vested share-based compensation	'	'	1,200,000	'	'	'	'
Stock-based compensation expense	'	'	700,000	600,000	500,000	'	'
Weighted-average period recognized	'	'	'2 years 3 months 22 days	'	'	'	'
Performance Units [Member]	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'
Stock-based compensation expense	'	'	1,100,000	'	'	'	'
Unrecognized compensation costs related to non-vested share-based compensation	'	'	900,000	'	'	'	'
Weighted-average period recognized	'	'	'2 years	'	'	'	'
Performance Units granted	'	'	389,864	'	'	'	'
Stock Options [Member]	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'
Restricted stock units granted	'	'	66,348	128,000	77,500	'	'
Restricted stock units [Member]	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'
Restricted stock units, market price	'	'	'	'	'	'	5.13
Maximum [Member] | Performance Units [Member]	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'
Performance Units vesting period	'	'	'5 years	'	'	'	'
Board of Directors [Member]	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'
Common stock awarded options	'	'	22,500	'	'	'	'
Board of Directors [Member] | Stock Options [Member]	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'
Share based payment granted fair values of option	'	'	180,000	225,000	168,000	'	'
IPO [Member]	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'
Number of shares of common stock sold	9,000,000	6,086,956	'	'	'	9,000,000	'
2006 Stock Incentive Plan [Member]	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'
Common stock authorized for issuance	'	'	9,927,700	'	'	'	'
Underwriters' [Member]	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'
Number of shares of common stock sold	546,474	913,044	'	'	'	546,474	'
Non-Employee Board [Member]	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'
Stock-based compensation expense	'	'	246,000	230,000	168,000	'	'
Value of non-qualified stock options and restricted stock units	'	'	45,000	'	'	'	'
Stock-based compensation expense related stock options	'	'	204,000	154,000	70,000	'	'
Value of units granted	'	'	$180,000	$225,000	$83,000	'	'
Non-Employee Board [Member] | Restricted stock units [Member]	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'
Performance Units vesting period	'	'	'1 year	'	'	'	'
Restricted stock units granted	'	'	38,216	74,750	25,000	'	'
Non-Employee Board [Member] | Maximum [Member] | Restricted stock units [Member]	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'
Stock options granted to purchase	'	'	'	'	5,000	'	'

Stockholders_Equity_Summary_of

Stockholders' Equity - Summary of Options (Detail) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Equity [Abstract]	'	'	'
Number of Shares, Options outstanding, beginning of year	5,726,874	5,799,100	6,471,975
Number of Shares, Options granted	1,216,729	759,900	349,000
Number of Shares, Options exercised	-535,730	-88,594	-59,126
Number of Shares, Options cancelled or forfeited	-1,099,256	-743,532	-962,749
Number of Shares, Options outstanding, end of year	5,308,617	5,726,874	5,799,100
Number of Shares, Options exercisable, end of year	4,121,942	4,572,716	4,686,364
Weighted Average Price, Options outstanding, beginning of year	$3.30	$3.72	$4.92
Weighted Average Price, Options granted	$4.79	$3.59	$3.40
Weighted Average Price, Options exercised	$3.36	$3	$2.91
Weighted Average Price, Options canceled or forfeited	$4.35	$6.96	$11.70
Weighted Average Price, Options outstanding, end of year	$3.41	$3.30	$3.72
Weighted Average Price, Options exercisable, end of year	$3.18	$3.21	$3.81

Stockholders_Equity_Options_Ou

Stockholders' Equity - Options Outstanding Under the Plan (Detail) (USD $)	12 Months Ended
	Jun. 30, 2014
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Number outstanding at June 30, 2014	5,308,617
Weighted average exercise price	$3.41
Weighted average remaining term (yrs.)	'3 years 5 months 9 days
Number exercisable at June 30, 2014	4,121,942
Weighted average exercise price	$3.18
1.59 - 3.00 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Range of exercise price, Minimum	$1.59
Range of exercise price, Maximum	$3
Number outstanding at June 30, 2014	2,078,288
Weighted average exercise price	$2.43
Weighted average remaining term (yrs.)	'1 year 6 months 22 days
Number exercisable at June 30, 2014	2,074,663
Weighted average exercise price	$2.43
3.01 - 5.00 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Range of exercise price, Minimum	$3.01
Range of exercise price, Maximum	$5
Number outstanding at June 30, 2014	2,505,448
Weighted average exercise price	$3.68
Weighted average remaining term (yrs.)	'4 years 1 month 21 days
Number exercisable at June 30, 2014	1,671,054
Weighted average exercise price	$3.67
5.01 - 7.00 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Range of exercise price, Minimum	$5.01
Range of exercise price, Maximum	$7
Number outstanding at June 30, 2014	724,881
Weighted average exercise price	$5.28
Weighted average remaining term (yrs.)	'6 years 4 months 21 days
Number exercisable at June 30, 2014	376,225
Weighted average exercise price	$5.21

Stockholders_Equity_NonVested_

Stockholders' Equity - Non-Vested Restricted Stock Units (Detail)	12 Months Ended
	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Non-vested at July 1, 2013	488,575
Vested/Exercised	-257,243
Forfeited	-25,000
Non-vested at June 30, 2014	788,364
Restricted Stock [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Granted	192,168
Performance Units [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Granted	389,864

Stockholders_Equity_Components

Stockholders' Equity - Components of Accumulated Other Comprehensive Income (Detail) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'
Beginning, Balance	$161,830	'	'
Net current-period other comprehensive income	100,007	81,669	-314,508
Ending, Balance	261,837	161,830	'
Accumulated Other Comprehensive Income [Member]	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'
Beginning, Balance	161,830	80,161	394,669
Net current-period other comprehensive income	100,007	81,669	-314,508
Ending, Balance	261,837	161,830	80,161
Other comprehensive income before reclassifications	107,524	'	'
Amounts reclassified from accumulated other comprehensive income	-7,517	'	'
Currency Translation Adjustments [Member]	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'
Beginning, Balance	161,830	80,161	394,669
Net current-period other comprehensive income	100,094	81,669	-314,508
Ending, Balance	261,924	161,830	80,161
Other comprehensive income before reclassifications	100,094	'	'
Net Unrealized Gains (Losses) on Available-for-Sale Securities [Member]	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'
Net current-period other comprehensive income	-87	'	'
Ending, Balance	-87	'	'
Other comprehensive income before reclassifications	7,430	'	'
Amounts reclassified from accumulated other comprehensive income	($7,517)	'	'

Stockholders_Equity_Components1

Stockholders' Equity - Components of Accumulated Other Comprehensive Income (Parenthetical) (Detail) (Accumulated Other Comprehensive Income [Member], USD $)	12 Months Ended
	Jun. 30, 2014
Accumulated Other Comprehensive Income [Member]	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'
Reclassified from accumulated other comprehensive income	$7,517

Earnings_Per_Share_Basic_and_D

Earnings Per Share - Basic and Diluted Earnings Per Share (Detail) (USD $)	3 Months Ended								12 Months Ended
	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Net (loss) income attributable to Immunomedics, Inc.	($11,847,000)	($9,506,000)	($8,873,000)	($5,201,000)	($7,683,000)	$8,609,000	($5,166,000)	($7,141,000)	($35,425,826)	($11,381,523)	$1,378,409
Basic earnings per share:	'	'	'	'	'	'	'	'	'	'	'
Weighted average basic common shares outstanding	'	'	'	'	82,737,000	78,196,000	75,671,000	75,610,000	84,631,567	78,040,005	75,481,007
Basic (loss) earnings per common share attributable to Immunomedics, Inc.	'	'	'	'	($0.09)	$0.11	($0.07)	($0.10)	($0.42)	($0.15)	$0.02
Diluted earnings per share:	'	'	'	'	'	'	'	'	'	'	'
Weighted average basic common shares outstanding	'	'	'	'	82,737,000	78,196,000	75,671,000	75,610,000	84,631,567	78,040,005	75,481,007
Weighted average diluted common shares outstanding	'	'	'	'	82,737,000	78,447,000	75,671,000	75,610,000	84,631,567	78,040,005	76,174,377
Diluted (loss) earnings per common share attributable to Immunomedics, Inc.	'	'	'	'	($0.09)	$0.11	($0.07)	($0.10)	($0.42)	($0.15)	$0.02
Stock Options [Member]	'	'	'	'	'	'	'	'	'	'	'
Diluted earnings per share:	'	'	'	'	'	'	'	'	'	'	'
Dilutive effect	'	'	'	'	'	'	'	'	'	'	611,000
Shares excluded from the weighted average diluted common shares outstanding because their inclusion would have been anti-dilutive	'	'	'	'	'	'	'	'	6,309,000	6,727,000	5,699,000
Restricted Stock [Member]	'	'	'	'	'	'	'	'	'	'	'
Diluted earnings per share:	'	'	'	'	'	'	'	'	'	'	'
Dilutive effect	'	'	'	'	'	'	'	'	'	'	82,000
Shares excluded from the weighted average diluted common shares outstanding because their inclusion would have been anti-dilutive	'	'	'	'	'	'	'	'	788,000	489,000	357,000

Income_Taxes_Provision_Benefit

Income Taxes - Provision (Benefit) for Income Taxes (Detail) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Income Tax Disclosure [Abstract]	'	'	'
Current	'	($38,000)	$126,000
Deferred	'	'	'
Total Federal	'	-38,000	126,000
Current	1,000	2,000	2,000
Deferred	'	'	'
Total State	1,000	2,000	2,000
Current	7,000	80,000	82,000
Deferred	'	'	'
Total Foreign	7,000	80,000	82,000
Total Expense	$7,791	$44,070	$209,785

Income_Taxes_Reconciliation_of

Income Taxes - Reconciliation of Statutory Tax Rates and Effective Tax Rates (Detail)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Income Tax Disclosure [Abstract]	'	'	'
Statutory rate	-34.00%	-34.00%	34.00%
State income taxes (net of Federal tax benefit)	0.00%	0.00%	0.30%
Foreign income tax	0.10%	0.10%	-3.20%
Change in valuation allowance	27.50%	12.10%	-716.20%
NOL expiration	0.00%	24.30%	754.50%
R&D tax credit expiration	0.00%	-3.40%	-72.80%
Other	6.40%	1.30%	17.60%
Effective rate	0.00%	0.40%	14.20%

Income_Taxes_Tax_Effects_of_Te

Income Taxes - Tax Effects of Temporary Differences in Deferred Tax Assets (Detail) (USD $)	Jun. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified
Income Tax Disclosure [Abstract]	'	'
NOL carry forwards	$66,699	$53,941
Research and development credits	12,264	11,707
Property and equipment	4,055	4,369
Other	5,479	8,705
Total	88,497	78,722
Valuation allowance	-88,497	-78,722
Net deferred taxes	'	'

Income_Taxes_Additional_inform

Income Taxes - Additional information (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014
Income Tax Disclosure [Abstract]	'
Operating loss carry forwards for federal income tax	$183.80
Operating loss carry forwards for state income tax	70.6
Tax deduction for non-qualified stock options	$20

Related_Party_Transactions_Add

Related Party Transactions - Additional Information (Detail) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Related Party Transaction [Line Items]	'	'	'
Minimum additional incentive compensation, royalty payments and disposition of undeveloped assets	$150,000	'	'
Minimum percentage of consideration from disposition paid to related party	20.00%	'	'
Term of contractual obligation	'3 years	'	'
Additional compensation	'	'	300,000
Compensation received for services	79,000	78,000	55,000
David M. Goldenberg Millennium Trust [Member]	'	'	'
Related Party Transaction [Line Items]	'	'	'
Additional incentive compensation during the agreement term	1.50%	'	'
Cynthia L. Sullivan [Member]	'	'	'
Related Party Transaction [Line Items]	'	'	'
Percentage of annual bonus target	50.00%	'	'
Current annual base salary	600,000	'	'
Center for Molecular Medicine and Immunology [Member]	'	'	'
Related Party Transaction [Line Items]	'	'	'
Area of subleased property	1,000	'	'
Subleases cost	30,000	'	'
Reimbursed expenses incurred on behalf of company	0	32,000	200,000
Legal expenses incurred by the company	26,000	60,000	68,000
Series A Preferred Stock [Member]	'	'	'
Related Party Transaction [Line Items]	'	'	'
Preferred stock liquidation preferences	$0.69	'	'
Series B Preferred Stock [Member]	'	'	'
Related Party Transaction [Line Items]	'	'	'
Preferred stock liquidation preferences	'	$5.17	'
Series C Preferred Stock [Member]	'	'	'
Related Party Transaction [Line Items]	'	'	'
Preferred stock liquidation preferences	'	'	$0.33
Minimum [Member] | Cynthia L. Sullivan [Member]	'	'	'
Related Party Transaction [Line Items]	'	'	'
Percentage potential payout based on performance	0.00%	'	'
Maximum [Member] | Cynthia L. Sullivan [Member]	'	'	'
Related Party Transaction [Line Items]	'	'	'
Percentage potential payout based on performance	150.00%	'	'
License Agreement [Member]	'	'	'
Related Party Transaction [Line Items]	'	'	'
Royalty percentage	0.50%	'	'
Annual net sales of products covered by patents	20,000,000	'	'
Royalty percentage, excess	0.25%	'	'
Additional incentive compensation during the agreement term	0.75%	'	'
Employment Agreement [Member] | David M. Goldenberg Millennium Trust [Member]	'	'	'
Related Party Transaction [Line Items]	'	'	'
Annual base salary	$500,000	'	'
Percentage of annual bonus target	50.00%	'	'
Employment Agreement [Member] | Minimum [Member] | David M. Goldenberg Millennium Trust [Member]	'	'	'
Related Party Transaction [Line Items]	'	'	'
Percentage of potential payout target	0.00%	'	'
Employment Agreement [Member] | Maximum [Member] | David M. Goldenberg Millennium Trust [Member]	'	'	'
Related Party Transaction [Line Items]	'	'	'
Percentage of potential payout target	150.00%	'	'

Related_Party_Transactions_Sch

Related Party Transactions - Schedule of IBC Pharmaceuticals, Inc. (Detail)	1 Months Ended
	Jun. 30, 2014
Related Party Transaction [Line Items]	'
Total ownership percentage	100.00%
Series A Preferred Stock [Member]	'
Related Party Transaction [Line Items]	'
Shares held by parent company	5,615,124
Immunomedics, Inc. [Member] | Series A Preferred Stock [Member]	'
Related Party Transaction [Line Items]	'
Percentage of shares held by parent company	73.46%
Third Party Investors [Member] | Series B Preferred Stock [Member]	'
Related Party Transaction [Line Items]	'
Shares held by David M. Goldenberg Millennium Trust	628,282
Percentage of shares held by David M. Goldenberg Millennium Trust	8.22%
David M. Goldenberg Millennium Trust [Member] | Series C Preferred Stock [Member]	'
Related Party Transaction [Line Items]	'
Shares held by David M. Goldenberg Millennium Trust	1,399,926
Percentage of shares held by David M. Goldenberg Millennium Trust	18.32%

License_and_Collaboration_Agre1

License and Collaboration Agreements - Additional Information (Detail) (USD $)

0 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

Dec. 27, 2011

Jan. 31, 2012

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2012

Dec. 27, 2011

Jun. 30, 2014

Dec. 27, 2011

9-May-06

Dec. 27, 2011

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Mar. 06, 2014

Jun. 30, 2014

UCB Agreement [Member]

UCB Agreement [Member]

UCB Agreement [Member]

UCB Agreement [Member]

UCB Agreement [Member]

UCB Agreement [Member]

Algeta Agreement [Member]

Algeta Agreement [Member]

Nycomed Agreement [Member]

Maximum [Member]

Guarantor Obligations [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Collaboration agreement date

'

'

'

'

'

'

'

'

'

'

'

'

'2013-01

'

'

Collaboration agreement amendment date

'

'

'

'

'

'

'

'

'

'

'

'

2-Aug-13

'

'

License fee revenue

'

'

'

'

'

'

'

$28,400,000

'

'

'

'

$4,600,000

'

'

Cost of license fee and other revenues

'

'

1,189,170

0

0

'

'

'

'

'

'

'

1,200,000

'

'

Percentage of shares voluntary takeover

'

'

'

'

'

'

'

'

'

'

'

'

'

98.20%

'

License agreement date

'

'

'

'

'

'

'

'

'

'

9-May-06

'

'

'

11-Jul-08

Acquisition completion date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

30-Sep-11

Non-refundable cash payment received

'

30,000,000

'

'

'

'

'

'

38,000,000

'

'

'

'

'

'

Amendment agreement date

'

'

'

'

'

'

'

'

27-Dec-11

'

'

'

'

'

'

Duration of warrant issued

'5 years

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

Number of shares under five year warrant

'

'

'

'

'

1,000,000

'

'

'

'

'

'

'

'

'

Shares to be purchased under warrant, par value

'

'

'

'

'

$0.01

'

'

'

'

'

'

'

'

'

Shares to be purchased under warrant, exercise price

'

'

'

'

'

$8

'

'

'

'

'

'

'

'

'

Cash payment receivable

'

'

'

'

'

'

'

'

'

'

'

145,000,000

'

'

'

Equity investments receivable

'

'

'

'

'

'

'

'

'

'

'

20,000,000

'

'

'

Achievement of specified product sales milestones

'

'

'

'

'

'

'

'

'

'

'

260,000,000

'

'

'

Product royalties term, description

'

'

'

'

'

'

'

'

'

'

'The Company is also entitled to product royalties ranging from mid-teen to mid-twenty percentage of aggregate annual net sales under the UCB Agreement during the product royalty term.

'

'

'

'

Termination period

'

'

'

'

'

'

'60 days

'

'

'

'

'

'

'

'

Additional amounts payable after effective date of termination

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

Fair value of warrant

'

'

'

'

'

'

'

'

'

$1,600,000

'

'

'

'

'

Common stock price volatility

'

'

'

'

'

'

'

'

'

80.00%

'

'

'

'

'

Market yield risk free interest rate

'

'

'

'

'

'

'

'

'

0.96%

'

'

'

'

'

Option price of warrant price at conversion

'

'

'

'

'

'

'

'

'

$8

'

'

'

'

'

Common stock price

'

'

'

'

'

'

'

'

'

$3.37

'

'

'

'

'

Dividend yield

'

'

'

'

'

'

'

'

'

0.00%

'

'

'

'

'

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Detail) (USD $)

0 Months Ended

12 Months Ended

12 Months Ended

0 Months Ended

Mar. 27, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2012

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Apr. 18, 2014

Center for Molecular Medicine and Immunology [Member]

Nycomed Agreement [Member]

Chief Scientific Officer and Chief Medical Officer [Member]

Operating Lease [Member]

2013 through 2016 [Member]

President and Chief Executive Officer [Member]

Class Action Lawsuits [Member]

First Lawsuit [Member]

Second Lawsuit [Member]

sqft

Chief Scientific Officer and Chief Medical Officer [Member]

Employment Agreement [Member]

Guarantor Obligations [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Agreement date

'

'

'

'

'

'

1-Jul-11

'

'

1-Jul-14

'

'

'

Annual base salary

'

'

'

'

'

'

'

'

'

$600,000

'

'

'

Salaries guaranteed

'

'

'

'

'

'

'

'

500,000

'

'

'

'

Guaranteed royalties

'

'

'

'

'

'

'

'

200,000

'

'

'

'

Leased space at the facility, square feet

'

'

'

'

1,000

'

'

'

'

'

'

'

'

Lease expiration date

'

'

'

'

'

'

'

31-Oct-31

'

'

'

'

'

Base annual rate

'

'

'

'

'

'

'

800,000

'

'

'

'

'

Rental expense

'

800,000

800,000

800,000

'

'

'

'

'

'

'

'

'

Agreement termination date

'

9-Oct-13

'

'

'

3-Oct-13

'

'

'

'

'

'

'

Lawsuit filing date

'

'

'

'

'

'

'

'

'

'

'2014-02-27

'March 24, 2014

'April 18, 2014

Arbitration settlement amount, gross

18,000,000

0

16,739,282

0

'

'

'

'

'

'

'

'

'

Net amount received after payment of expenses and legal fees

$16,700,000

'

'

'

'

'

'

'

'

'

'

'

'

Commitments_and_Contingencies_2

Commitments and Contingencies - Schedule of Minimum Lease Commitments for Facilities (Detail) (USD $)	Jun. 30, 2014
In Thousands, unless otherwise specified
Commitments And Contingencies Disclosure [Abstract]	'
2015	$838
2016	838
2017	929
2018	974
2019	974
Thereafter	$12,710

Geographic_Segments_Financial_

Geographic Segments - Financial Information Based on Geographic Location of Facilities (Detail) (USD $)	3 Months Ended								12 Months Ended
	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Total assets	$46,843,905	'	'	'	$47,927,353	'	'	'	$46,843,905	$47,927,353	$38,635,000
Property and equipment, net	1,895,475	'	'	'	2,086,911	'	'	'	1,895,475	2,086,911	2,528,000
Revenues	1,188,000	1,154,000	1,202,000	5,498,000	1,363,000	1,736,000	812,000	1,051,000	9,041,605	4,961,997	32,733,827
(Loss) income before income tax expense	'	'	'	'	'	'	'	'	-35,523,387	-11,442,214	1,474,620
United States [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Total assets	44,284,000	'	'	'	45,552,000	'	'	'	44,284,000	45,552,000	35,570,000
Property and equipment, net	1,895,000	'	'	'	2,087,000	'	'	'	1,895,000	2,087,000	2,528,000
Revenues	'	'	'	'	'	'	'	'	5,947,000	2,011,000	29,248,000
(Loss) income before income tax expense	'	'	'	'	'	'	'	'	-35,452,000	-11,630,000	1,149,000
Europe [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Total assets	2,560,000	'	'	'	2,375,000	'	'	'	2,560,000	2,375,000	3,065,000
Property and equipment, net	'	'	'	'	'	'	'	'	'	'	'
Revenues	'	'	'	'	'	'	'	'	3,095,000	2,951,000	3,486,000
(Loss) income before income tax expense	'	'	'	'	'	'	'	'	($71,000)	$188,000	$325,000

Defined_Contribution_Plans_Add

Defined Contribution Plans - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Postemployment Benefits [Abstract]	'	'	'
Aggregate Company contributions to its benefit plans	$96	$98	$95

Subsequent_Event_Additional_In

Subsequent Event - Additional Information (Detail)	12 Months Ended
	Jun. 30, 2014
Subsequent Event [Line Items]	'
Current annual base salary	600,000
Annual bonus target percentage	50.00%
Agreement termination date	9-Oct-13
Employment Agreement [Member] | Sullivan Agreement [Member]	'
Subsequent Event [Line Items]	'
Agreement termination date	1-Jul-17
Minimum [Member]	'
Subsequent Event [Line Items]	'
Percentage of potential payout	0.00%
Maximum [Member]	'
Subsequent Event [Line Items]	'
Percentage of potential payout	150.00%

Quarterly_Results_of_Operation2

Quarterly Results of Operations - Summarized Unaudited Quarterly Financial Data (Detail) (USD $)	3 Months Ended								12 Months Ended
	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Consolidated Statements of Comprehensive Loss Data:	'	'	'	'	'	'	'	'	'	'	'
Revenues	$1,188,000	$1,154,000	$1,202,000	$5,498,000	$1,363,000	$1,736,000	$812,000	$1,051,000	$9,041,605	$4,961,997	$32,733,827
Net (loss) income attributable to Immunomedics, Inc.	($11,847,000)	($9,506,000)	($8,873,000)	($5,201,000)	($7,683,000)	$8,609,000	($5,166,000)	($7,141,000)	($35,425,826)	($11,381,523)	$1,378,409
(Loss) income per common share attributable to Immunomedics Inc. - basic	'	'	'	'	($0.09)	$0.11	($0.07)	($0.10)	($0.42)	($0.15)	$0.02
Loss per common share attributable to Immunomedics Inc. - basic and diluted	($0.13)	($0.11)	($0.12)	($0.06)	'	'	'	'	'	'	'
(Loss) income per common share attributable to Immunomedics Inc. - fully diluted	'	'	'	'	($0.09)	$0.11	($0.07)	($0.10)	($0.42)	($0.15)	$0.02
Weighted average shares used to calculate loss per common share - basic and diluted	89,084,000	83,340,000	83,175,000	82,947,000	'	'	'	'	'	'	'
Weighted average shares used to calculate loss per common share - basic	'	'	'	'	82,737,000	78,196,000	75,671,000	75,610,000	84,631,567	78,040,005	75,481,007
Weighted average shares used to calculate loss per common share - diluted	'	'	'	'	82,737,000	78,447,000	75,671,000	75,610,000	84,631,567	78,040,005	76,174,377

Schedule_II_Valuation_and_Qual1

Schedule II - Valuation and Qualifying Reserves (Detail) (Allowance for Doubtful Accounts [Member], USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Allowance for Doubtful Accounts [Member]	'	'	'
Valuation and Qualifying Accounts Disclosure [Line Items]	'	'	'
Balance at Beginning of Year	($49,265)	($54,809)	($32,012)
Changes to Reserve	-39,344	5,544	-22,797
Credits to Expense	'	'	'
Other Charges	'	'	'
Balance at End of Year	($88,609)	($49,265)	($54,809)